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Candida species are an important cause of nosocomial bloodstream infections 
in hospitalized patients worldwide. Candidemias increase hospital stay and are 
associated with high mortality. 
In this study, the epidemiology of candidemia in Finland was described over two 
periods of population-based surveillance and over an 18-year study in Helsinki 
University Central Hospital. An epidemiological study of blood stream infections 
caused by C. albicans strains was executed using molecular typing method.   
The incidence of candidemia in Finland increased between 1990s and 2000s. 
Age-spesific differences in incidence were identified. In HUCH the incidence of 
candidemia remained low, but a significant shift in patient-populations at risk 
was observed. The predominating causative species was C. albicans, but the 
proportions of other Candida spp.  changed.  
This study adds to our understanding of candidemias. Continued surveillance is 
necessary to detect possible changes in incidence, causative species and patient 
groups at risk, and thus guide the implementation of preventive measures. 
Molecular methods serves as a basis for epidemiological survey of suspected 
outbreaks. 
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Abstract
Eira Poikonen. Epidemiology of Candidemia in Finland. National Institute for 
Health and Welfare (THL), Research 54/2011. 115 pages. Helsinki, Finland 2011.
ISBN 978-952-245-447-8 (printed), ISBN 978-952-245-448-5 (pdf)
Background and aims. Candida species are an important cause of nosocomial 
bloodstream infections (BSIs) in hospitalized patients worldwide, with associated 
high mortality, excess length of stay and costs. Main contributors to candidemias are 
intensive treatments, complex gastroenterology surgery, prolonged and profound 
immunosuppression, invasive monitoring and broad spectrum antibiotic treatments 
leading to an increasing number of susceptible patients. The rank order of causative 
Candida species varies over time and in different geographic locations. The aim of 
this study was to obtain information on epidemiology of candidemia in Finland, 
to identify trends in incidence, causative species, and patient populations at risk 
as well as the contribution of fluconazole consumption and prophylaxis policies 
in tertiary care centers (TCCs) to the epidemiology of these infections. In order 
to reveal possible outbreaks and assess the value of one molecular typing method, 
restriction enzyme analysis (REA), in epidemiological study, we analyzed C. albicans 
bloodstream isolates in Uusimaa region in Southern Finland during eight years.   
Methods. All microbiology laboratories in Finland have reported all bacterial and 
fungal isolations from blood to the National Infectious Disease Register (NIDR) since 
1995. The data from NIDR were used to assess the incidence and epidemiological 
features of candidemia cases during two separate periods during 1995–1999 and 
2004–2007. Data on fluconazole consumption in Finland was obtained from 
National Agency of Medicines (currently FIMEA). Infectious diseases specialists 
were interviewed for regional antifungal prophylaxis policies. In Helsinki University 
Central Hospital (HUCH) all patients with blood culture yielding any Candida 
spp. were identified from laboratory log-books during 1987-1998 and during 1999-
2004 from Finnish Hospital Infection Program (SIRO). Patient characteristics and 
outcome were assessed through chart review and data from this register. Data on 
fluconazole use were obtained from hospital pharmacy. 
During 1986–1995, all patients with a stored blood culture isolate of C. albicans 
were identified through microbiology laboratory logbooks for epidemiologal typing. 
Place of treatment and patients characteristics were identified through chart review. 
Stored C. albicans isolates were genotyped with REA (using two enzymes) in the 
National Institute for Health and Welfare (former KTL).  
Results. During 1995–1999 the annual incidence of candidemia in Finland 
increased from 1.7 to 2.2 per 100,000 population. The incidence rose in men 16–65 
years of age. C. albicans accounted for 70% of cases without a change in proportion. 
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Compared to the 1990s, during 2004–2007 the average annual incidence rate was 
higher, 2.9 per 100,000 population, (range by year 2.6–3.1), without increasing 
trend. The incidence was highest in males >65 years of age, but incidence rates for 
patients <1–15 years were lower than during 1990s. C. albicans accounted for 67% of 
cases, while C. glabrata ranked the second. The crude case-fatality rate in one month 
varied between 28–32% during 2004–2007. Fluconazole consumption increased 
in Finland from 19.57–25.09 defined daily doses (DDDs) per 100,000 population 
during 2000–2007. Fluconazole prophylaxis was routinely used in patients treated 
for acute leukemias, liver transplant recipients, and in premature infants.
In HUCH the annual incidence varied from 0.26 to 0.59 per 10,000 patient 
days, without any trend. The most common species was C. albicans (65%), while C. 
parapsilosis ranked the second (13%) and C. glabrata the third (9%). The proportion 
of C. albicans decreased from 71% to 58%, while the proportion of C. glabrata 
increased from 3% to 14% during observation. Patients treated in intensive care 
units increased from 27% to 44%, associated with surgical patients and newborns. 
The one-month case fatality ranged between 30–33%. 
REA differentiated efficiently between C. albicans blood culture isolates, and 
demonstrated highly reproducible DNA patterns among consecutive isolates from 
the same patient. No clusters or endemic subtypes were observed in the seven acute 
care hospitals involved, despite of abundant transfer of patients among them. 
Conclusions. The incidence of candidemia in Finland is globally relatively low, but 
increased between between 1990s and 2000s. In HUCH the incidence of candidemia 
remained low and constant, but a significant shift in patient-populations at risk was 
observed, associated with surgical and intensive care patients. Candida spp. are an 
important cause of nosocomial blood stream infections in Finland, and continued 
surveillance is necessary to determine the overall trends and patient groups at 
risk, and reduce the impact of these infections in the future. The predominating 
causative species in Finland and in HUCH is C. albicans, but the proportion of 
C. glabrata increased considerably. The fluconazole consumption increased in all 
five TCC regions in Finland, and systematic fluconazole prophylaxis was used in 
traditional high-risk patient groups. The possible role of antifungal prophylaxis with 
fluconazole in the shift of patient populations at risk and in causative Candida spp. 
should be addressed in the future. The crude case fatality proportion by one month 
was constantly high. Considering this and the difficulties in administering early and 
adequate antifungal therapy, better measures of prevention will offer better options 
to reduce candidemia associated mortality. Epidemiological typing of C. albicans 
did not show any clusters or endemic subtypes in the hospitals involved. Molecular 
methods provide an efficient tool for investigation of suspected outbreak and should 
be available in the future in Finland, also.
Keywords: candidemia, invasive candida infections, epidemiology, molecular typing, 
outcome, Candida spp., C. albicans
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Tausta ja tavoitteet. Kandidahiivat ovat merkittäviä sairaalahoitoon liittyvien ve-
riviljelypositiivisten infektioiden aiheuttajia maailmanlaajuisesti. Kandidemia pait-
si pidentää sairaalapotilaiden hoidon kestoa ja siten lisää kustannuksia, myös lisää 
kuolleisuutta. Kandidemialle ovat alttiita eryisesti potilaat, joiden puolustuskyky 
infektioille on alentunut vaikean perussairauden, immuunipuolustusta lamaavien 
hoitojen, tai vaikeiden invasiivisten toimenpiteiden, leikkausten ja monitoroinnin 
vuoksi. Myös keskosuus ja laajakirjoinen bakteerilääkitys altistavat kandidemioille. 
Yleisin aiheuttaja maailmanlaajuisesti on Candida  albicans, mutta pääasiallinen hii-
vapatogeeni vaihtelee eri aikoina ja eri maissa ja keskuksissa. Vaikkakin suurimmas-
sa osassa kandidemioita aiheuttaja on peräisin potilaan omasta mikrobistosta, on 
myös sairaalaympäristöstä peräisin olevia epidemioita kuvattu. 
Tämän tutkimuksen tarkoituksena oli selvittää kandidahiivojen aiheuttamien 
veriviljelypositiivisten infektioiden ilmaantuvuutta, aiheuttajalajeja ja kuolleisuutta 
sairaalapotilailla Suomessa. Lisäksi tutkittiin, mitkä potilasryhmät näitä infektioita 
sairastavat ja mikä vaikutus hiiva-antibiootti flukonatsolin käytöllä sekä yliopistos-
airaaloiden flukonatsoliprofylaksikäytännöillä on kandidemioiden ilmaantuvuuteen 
ja aiheuttajakirjoon. Helsingin-Uudenmaan alueen sairaaloissa hoidetut C. albican-
sin aiheuttamat kandidemiat tutkittiin kahdeksan vuoden ajalta ja laboratorion näis-
tä potilaista tallentamat hiivakannat tutkittiin epidemiologisella tyypitysmenetel-
mällä.   
    
Menetelmät. Suomen valtakunnallisesta tartuntatautirekisteristä (NIDR) selvitettiin 
potilaat, joilta veriviljelyssä oli kasvanut kandidahiiva vuosilta 1995–1999 ja 2004–
2007. Tartuntatautirekisteriin ilmoitettujen tietojen perusteella voitiin laskea kandi-
demioiden ilmaantuvuus eri ikäryhmissä ja eri yliopistosairaala-alueilla Suomessa. 
Tapauksiin liittyvä kuolleisuustieto kuukauden kuluttua infektion toteamisesta oli 
saatavilla vuosille 2004–2007. Lääkelaitokselta (nykyinen FIMEA) saatiin tiedot flu-
konatsolin käytöstä yliopistosairaala-alueittain vuosilta 2000–2007. Kunkin viiden 
yliopistosairaalan infektioerikoislääkäri haastateltiin puhelimitse ja selvitettiin flu-
konatsolin käyttö sieni-infektioiden estolääkityksenä eri potilasryhmissä sekä lap-
si- että aikuispotilailla.  
Helsingin Yliopistollisen Keskussairaalan (HYKS) kandidahiivojen aiheutta-
mat veriviljelypositiiviset infektiot selvitettiin mikrobiologian laboration raport-
tien perusteella vuosilta 1987–1998 ja valtakunnalliseen sairaalainfektio-ohjelmaan 
(SIRO) kerättyjen tietojen perusteella vuosilta 1999–2004. Kliiniset tiedot hoitopai-
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koista, leikkauksista, ja vierasesineistä kerättiin potilasasiakirjoista vuosilta 1987–
1998, vuosilta 1999–2004 käytettiin vain SIRO-rekisteriin kerättyjä tietoja. Lisäksi 
selvitettiin HYKS:n hallinnosta hoitopäivien määrä tutkimusajalta ja sairaala-aptee-
kista flukonatsolin käyttömäärät vuosilta 1991–1999 ja 2003–2004. Mikrobiolo gian 
laboratoriosta selvitettiin otettujen veriviljelyiden määrät ja elinsiirtoja ja luuytimen 
tai veren kantasolusiirtoja tekevistä yksiköistä tehtyjen elinsiirtojen määrät tutki-
musajalta. 
Mikrobiologian laboratorion raporttien perusteella poimittiin potilaat, joiden 
veriviljelyssä oli kasvanut C. albicans hiiva vuosina 1986–1995. Tutkimukseen va-
littiin ne potilaat, joiden hiivakanta oli talletettu ja joita oli hoidettu Helsingin-Uu-
denmaan alueen sairaaloissa. Potilasasiakirjoista kerättiin kliiniset tiedot ja potilaita 
hoitavat osastot. Tallennetut C. albicans -hiivakannat tutkittiin Terveyden ja Hyvin-
voinnin Laitoksen (silloinen KTL) laboratoriossa genotyyppiin perustuvalla tyypi-
tysmenetelmällä, restriktioentsyymianalyysilla (REA). 
Tulokset. Kandidemiat lisääntyivät tutkimusaikana: 1995 todettiin 1,7 tapaus-
ta/100 000 asukasta ja 1999 2,2 tapausta/100 000 asukasta. Tapaukset lisääntyivät 
erityisesti 16–65-vuotiailla miehillä. Candida albicans aiheutti 70 % kandidemiois-
ta. Vuosien 2004–2007 aikana ilmaantuvuus ei noussut, mutta oli korkeampi kuin 
1990-luvulla, keskimäärin 2,9 tapausta/100 000 asukasta (vuosittainen vaihtelu 2,6–
3,1/100 000). Ilmaantuvuus 2000-luvulla oli korkein >65-vuotiailla miehillä, mutta 
nuorilla <1–15-vuotiailla tapauksia oli vähemmän kuin kuin 1995–1999. Pääasialli-
sin aiheuttaja oli edelleen C. albicans, osuus 67 %,  mutta C. glabratan osuus lisääntyi 
niin, että 2000-luvulla se oli toiseksi yleisin hiivasepsisten aiheuttaja. Potilaiden ko-
konaiskuolleisuus kuukauden kuluttua infektion toteamisesta oli 35 % (vuosittainen 
vaihtelu 32–38 %) vuosina 2004–2007. Flukonatsolin käyttö lisääntyi Suomessa niin, 
että vuonna 2000 se oli 19,57 DDD (defined daily dose)/100 000 asukasta ja vuonna 
2007 25,09 DDD 100 000 asukasta. Flukonatsolia käytettiin rutiinisti lähes jokaises-
sa yliopistosairaalassa hiivainfektioiden estolääkityksenä akuuttia leukemiaa sairas-
tavilla, maksansiirtopotilailla ja keskosilla. 
HYKS:ssä vuosittainen kandidemioiden ilmaantuvuus vaihteli välillä 0,26–0,59 
tapausta/10 000 hoitopäivää eikä merkittävää lisääntymistä todettu. Yleisin aiheutta-
ja oli C. albicans (osuus 65 %), toiseksi yleisin oli C. parapsilosis (osuus 13 %), ja kol-
manneksi yleisin oli C. gblabrata (osuus 9 %). C. albicansin osuus väheni, sillä vuo-
sina 1987–1992 se aiheutti 71 % tapauksista ja vuosina 1999–2004 58 %, kun taas C. 
glabratan osuus lisääntyi ollen 3 % vuosina 1987–1992 ja 14 % vuosina 1999–2004. 
Teho-osastoilla hoidettujen ja varsinkin kirurgisten potilaiden osuus lisääntyi, sa-
moin kuin vastasyntyneiden (keskosten) osuus. Potilaista kuoli 30–33 % kuukauden 
kuluessa infektiosta. 
REA erotteli hyvin veriviljelyistä todetut C. albicans kannat, ja pystyi toisaalta 
osoittamaan samasta potilaasta otetuissa toistetuissa näytteissä identtisen kannan. 
Ryvästymiä tai epidemioita ei todettu huolimatta siitä, että potilaita siirrettiin usein 
akuuttisairaalasta ja hoitopaikasta toiseen.  
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Johtopäätökset. Kandidahiivojen aiheuttamien veriviljelypositiivisten infektioi-
den määrä Suomessa on maailmanlaajuisesti katsottuna pieni, mutta se on lisään-
tynyt 2000-luvulla 1990-lukuun verrattuna. HYKS:ssä kandidemioiden määrä ei 
18 vuoden aikana lisääntynyt, mutta tapauksia ilmaantui seurannan aikana use-
ammin teho-osastoilla hoidetuille potilaille, kuten kirurgisille potilaille ja keskosil-
le. Kandidalajit ovat edelleen Suomessa merkittävä veriljelypositiivisten infektioi-
den aiheuttaja, joten myös tulevaisuudessa näiden infektioiden ilmaantuvuuden ja 
aiheut tajalajien seuranta on tärkeää. Kandidemioille alttiit potilaat ja potilasryhmät 
on pyrittävä tunnistamaan, jotta infektioiden torjuntatoimia tehostamalla voidaan 
vähentää niiden aiheuttamaa tautitaakkaa ja siten estää niiden aiheuttamaa kuol-
leisuutta. Siitä huolimatta, että C. albicans on edelleen kandidemioiden pääasialli-
sin aiheuttaja, C. glabratan merkitys on lisääntynyt. Flukonatsolin käyttö lisääntyi 
kaikkien viiden yliopistosairaalan alueella ja sitä käytetään hiivainfektioprofylaksiin 
perinteisten riskiryhmien potilailla. Flukonatsoliprofylaksin merkitys toisaalta kan-
didemioille alttiisiin potilasryhmiin ja toisaalta kandidemioiden lajikirjoon voidaan 
arvioida vasta seurannassa. Potilaiden kokonaiskuolleisuus kuukauden kuluessa in-
fektiosta säilyi vakaasti korkeana. Huomioiden kandidemiaan liittyvä korkea kuol-
leisuus, diagnoosin vaikeudet ja siten antibioottihoidon riittämättömyys tai viiväs-
tyminen, näiden infektioiden ennaltaehkäisy todennäköisesti parantaisi potilaiden 
ennustetta. Epidemiologinen tutkimus C. albicansin aiheuttamista kandidemioista 
ei osoittanut ryvästymiä tutkituissa sairaaloissa. Molekylaariset tyypitysmenetelmät 
ovat tarpeen epidemiaselvityksissä ja sellainen tulisi olla kandidoille käytettävissä 
myös Suomessa. 
Asiasanat: Kandidemia, syvä kandidainfektio, epidemiologia, molekulaariset tyypi-
tysmenetelmät, kuolleisuus, Kandidalaji, Candida
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1	 Introduction
Bloodstream infections (BSIs) caused by yeasts of the Candida genus pose a serious 
threat to hospitalized patients worldwide. Candida species are the fourth leading 
cause of nosocomial bloodstream infections in the USA, accounting for 7–10% of 
all BSIs in hospital patients [1–3]. In Europe, Candida species ranks 7th to 8th among 
bloodstream pathogens in hospitalized patients, accounting for 4–6% of BSIs [4, 5]. 
Candidemias considerably prolong hospitalization and increase the use of healthcare 
resources—especially costs—as these infections complicate the care of already 
expensive groups of patients, such as the immunocompromized and critically ill 
[6–8]. The crude and attributable mortality rates associated with candidemias have 
remained high, which suggest that prevention of these infections would improve the 
prognosis of the patients. 
Reported incidences of candidemias vary globally. The incidence rates of 
candidemia considerably increased in the USA during the 1980s and early 1990s [1, 2], 
while through the 1990–2000s the rates appear to remain stable [2]. The incidence 
of candidemia also increased during the 1990s in Canada, Australia and Europe, 
but the reported rates have mostly been lower than in the USA [9–12]. Reasons 
for the rising candidemia rates include improved detection and, more importantly, 
an increase in the patient population at risk, as the use of invasive procedures and 
devices, broad-spectrum antimicrobial agents, advanced life-support and aggressive 
chemotherapy have become more frequent. The risk for candidemias is high in 
patients in the extremes of age (preterm neonates and patients >65 years of age) who 
survive longer with modern treatments. Prior to 1990, candidemias occurred mostly 
in immunosuppressed patients treated for hematological or solid malignancies, but 
the incidence of candidemias has more recently increased among non-neutropenic 
surgical and critically ill patients treated in intensive care units. 
The rank order of causative species differs between countries and over 
time. C. albicans is the predominant causative organism, but an increase in the 
incidence of non-C. albicans species has been observed in several centers [13–15], 
althoug not invariably [16, 17]. The precise distribution of causative species varies 
across countries and units, for reasons which remain unclear, but may be in part 
attributable to differences in underlying diseases treated, the types and intensities 
of treatments and antibiotics used, and other local factors. The emergence of less 
susceptible Candida species is a matter of concern, but the precise role of antifungal 
drug pressure in promoting the shift towards non-C. albicans species remains to be 
defined.   
BSIs caused by Candida species lack special clinical findings and fast sensitive 
diagnostic methods, which can complicate their timely recognition and treatment. 
To avoid delays in the treatment of candidemia thus worsening the prognosis, 
prophylactic, empirical, and pre-emptive antifungal treatment strategies have been 
1   Introduction
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developed. But because the identified risk factors for candidemias are all so common 
among immunocompromised patients and those treated in intensive care units, 
additional meaningful stratification of these factors is needed to identify the best 
targets for various treatment strategies [2, 18]. 
Because the prevalence of risk factors and changes in population demographics 
predisposing to candidemias are increasing surveillance has become essential. 
Studies that include selected hospitals or patient populations not only target the 
defining of risk factors, the distribution of causative species, the antimicrobial 
susceptibility of the pathogen in question, and its nosocomial spread in a preselected 
setting, but also allow for observation over prolonged periods of time. Population-
based studies, on the other hand, permit the calculations of incidence and mortality 
rates. The systematic analysis of possible outbreaks, although a minority, is important 
in defining the mode of transmission and evaluating the control measures and 
monitoring of infection in special areas where infection is a particular hazard. 
  The purpose of this study was to investigate the epidemiology of Candida 
bloodstream infections in Finland and particularly in the Helsinki University Central 
Hospital. With special emphasis on the largest tertiary care center in Finland, we 
could analyze the impact of molecular typing methods in outbreak surveys, and 
evaluate the shift in the patient population at risk and in the distribution of causative 
species over a prolonged period of time. The surveillance data available from 
National Infectious Diseases Register since 1995 enabled us compare the incidence 
rates, regional variation and outcome of candidemias during two separate periods 
in the face of increasing high-risk activities, and thus patient populations at risk for 
Candida blood stream infections.
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2	 Review	of	the	literature
2.1 The cause and impact of candida infections 
2.1.1  Candida species 
With more than 200 species that have been described, Candida is ubiquitous. Some 
species are normal habitants of the human microbiological flora of the skin, as 
well as the gastrointestinal, genitourinary, and even respiratory tracts [19, 20] but 
only 10% are known to cause infections in humans [21, 22]. Five most common 
species (i.e., Candida albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. 
krusei) cause 95–97% of human candidemias [2, 3, 23, 24]. The remaining 3–5% of 
Candida bloodstream infections (BSIs) are caused by 12–14 different species, and 
although these are considered rare causes of candidemias, several have occurred 
in nosocomial clusters and exhibit innate or acquired resistance to one or more 
established antifungal agents [20, 24–26].   
Main species causing candidemias possess unique properties that by interacting 
with local factors, may influence the epidemiology of these infections. All five main 
species are capable of forming biofilms in vitro, which confers upon them resistance 
to antimicrobials and host defence mechanisms [27–29]. Dimorphism and 
phenotypic switching in vitro and in vivo may potentiate adherence to and invasion 
of epithelial cells by C. albicans [20, 30]. C. parapsilosis can readily colonize the skin 
and persist in the hospital environment, thus leading to potential nosocomial spread 
by hand carriage [31, 32]. C. krusei is intrinsically resistant to fluconazole and often 
demonstrates decreased susceptibility to other antifungal agents (i.e., amphotericin 
B and flucytosine). C. glabrata, on the other hand, can easily acquire a resistance to 
fluconazole and other azole antifungal agents [2, 15].        
2.1.2  Sources
The primary origin of candidemia has been the subject of debate, with some 
suggesting endogenous while others favouring exogenous acquisition. The most 
important of these is considered as the endogenous acquisition of infection, which 
is implied when candidemia results from a previously colonizing Candida strain. 
Most evidence points to the importance of the patient’s own gastrointestinal flora as 
the source of candidemia [33–40]. In hematological patients antibacterial treatment 
has been shown to promote intestinal colonization by fungi [33]. 
The exogenous origin of candidemia is implied when the causative pathogen 
is acquired from the hospital environment or a human source during a hospital 
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stay [41]. The transmission of exogenous Candida strains may occur through 
direct contact or indirectly via hospital personnel (e.g., hand-carriage of Candida 
strains of healthcare worker (HCW), thus inducing colonization and possibly 
infection [42–46]. The cutaneous (exogenous) origin of candidemia is particularly 
debated in association with C. parapsilosis candidemia and intravascular catheters, 
as well as in patients with extensive burns [13, 47]. The colonization of skin may 
also originate from the gastrointestinal tract, as has occurred in neonates [48]. The 
direct exogenous acquisition of candidemia has also resulted from contaminated 
intravenous solutions and medical devices [29, 49].
2.1.3  Definitions and types of candida infections  
Colonization is defined as the multiplication of micro-organism at body sites of a 
host unaccompanied by clinical symptoms or immune response. Infection implies 
the replication of the pathogen in question in the tissues of a host, causing systemic 
or localized subclinical or clinical adverse reactions [50]. 
Nosocomial BSI is defined as the culture of a recognized pathogen in the 
bloodstream of a patient who has been hospitalized for >48 h, thus an infection 
that is absent or incubating when the patient is admitted to the hospital, in contrast 
to community-acquired BSI [51, 52]. Although >48 h after admission is generally 
deemed indicative of nosocomial acquisition of the infection in question, each case 
must be assessed individually for evidence that links it to hospitalization. Nosocomial 
BSIs may occur as outbreaks when the incidence rates increase above the expected 
or the usually observed rate [53].
The spectrum of diseases associated with Candida species is wide, and while 
superficial candidiasis of the skin and mucocutaneus surfaces are clearly the most 
frequent, candida may also cause life-threatening invasive infections, candidemia, 
and systemic or disseminated candidiasis. Candidemia refers to a condition where 
Candida species are isolated from the blood culture. Candidemia often involves 
disease outside of the bloodstream and frequently associates with a sepsis syndrome 
[54]. In clinical situations, as a rule, one positive blood culture for Candida spp. 
is deemed significant. Disseminated candidiasis, on the other hand, refers to a 
condition where an invasion of Candida is shown by culture or histology results of 
normally sterile tissues with or without candidemia [55]. 
The European Organization for Research and Treatment of Cancer/Invasive 
Fungal Infections Cooperative Group (EORTC) and National Institute of Allergy and 
Infectious Diseases Mycoses Study Group have created an international consensus 
defining invasive fungal infections for immunocompromised patients with cancer 
and hematopoietic stem cell transplants intended for use in the context of clinical 
or epidemiological research [56]. This consensus classifies candidemias by their 
level of certainty for the diagnoses (i.e., as “proven” or “probable”) in association 
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with mycological evidence from clinical specimens and temporally related clinical 
symptoms of infection. 
2.1.4  Public health impact
Candidemia represents a considerable burden in hospitalized patients contributing 
significantly to morbidity, mortality and increased cost and length of hospital stay.  
Morbidity
Candida has emerged worldwide as an important cause of nosocomial BSIs. In 
the USA during the 1980s, candidemias increased, accounting for 7–10% of all 
nosocomial BSIs, yet during the 1990s and 2000s, Candida spp. ranked the fourth 
most common causative pathogen in nosocomial BSIs [1–3, 57–61]. In Europe, 
candidemias increased during the 1990s, accounting for 3–9% of all nosocomial 
BSIs and ranking the seventh to eight most common causative pathogen isolated 
[5, 62–65]. In intensive care patients during the 1990s–2000s, Candida spp. caused 
11–12% of nosocomial BSIs in the USA and accounted for 6–9% in Europe [66–
70]. Candidemias accounted for 7–9% of all BSIs among adult and pediatric cancer 
patients [71, 72]. In HIV-patients, Candida spp. caused 19% of all nosocomial BSIs 
in a study from Italy, but highly active antiretroviral therapy has decreased the 
incidence of nosocomial infections these patiens [73, 74]. 
Mortality
The mortality associated with candidemia is substantial in both children and adults, 
much higher than should be expected to result from the underlying disease alone. 
The reported all-cause mortality has ranged from 30–61% in candidemia patients, 
and its attributable mortality from 5–49% [1, 6, 8, 75–78]. 
Cost and length of hospital stay 
Candidemia has an enormous impact on the utilization of medical resources 
and costs. The largest component of total costs is the prolonged length of stay 
(LOS) in hospital. The increase in total hospital charges were USD 33,604–45,602 
(mean USD 39,000) for an adult candidemia patient, USD 65,058–119,474 (mean 
USD 92,266) for a pediatric patient, and USD 1,374–76,715 (mean USD 39,045) for 
a neonate with candidemia in the USA [8, 78, 79]. Another report from the USA 
calculated an increase in total hospitals charges in the range of USD 6,000–29,000 
per candidemia patient in a mixed patient population and USD 28,000 for a neonate 
with candidemia [6, 80]. A recent report from the USA estimated that each one-
day delay in empirical therapy for candidemia was associated with increased total 
hospital costs of USD 6,392 ± 3,000 during 2002–2004 [81]. A Spanish study reported 
an additional cost of almost EUR 16,000 per patient due to Candida infection in 
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intensive care patients during 1998–1999 [7]. The reported increase in average LOS 
in hospitalized patients with candidemia has varied between 3–22 days and 4–12 
days in intensive care patients [6–8, 75, 79]. 
2.1.5  Surveillance 
Surveillance provides information on the incidence rates and outcome of 
candidemias as well as patterns of antifungal susceptibility of the causative 
pathogens, thus enabling the detection of outbreaks and assessment of the impact of 
prevention strategies and treatment. Surveillance systems differ between countries, 
which complicates the comparison of data they produce. Important issues include 
whether surveillance is active or passive; nationwide, regional or based on selected 
institutions; and statutory or voluntary. Most existing surveillance systems can be 
categorized into population-based or sentinel surveillance programs that target 
either the overall rates and causative pathogens of nosocomial infections (including 
BSIs), only infections caused by Candida species, or special patient groups at risk 
(such as intensive care patients). 
Population-based surveillance 
Population-based surveillance studies were conducted in the USA by the Centers 
for Disease Control and Prevention (CDC) and by the Emerging Infections and the 
Epidemiology of Iowa Organisms (EIEIO) surveillance program during the 1990s. 
Reporting was laboratory based, voluntary, and limited to a certain geographical area 
[23, 82–84]. In Europe, several countries have their own ongoing laboratory based, 
voluntary ,or statutory reporting system of bloodstream pathogens, which provides 
data for population-based incidence rates [17, 64, 85–87]. Also, during 2002–2003, 
a prospective population-based surveillance of candidemia was conducted in the 
greater Barcelona area in Spain [88, 89]. 
Sentinel surveillance 
In the USA, the Surveillance and Control of Pathogens of Epidemiologic Importance 
(SCOPE) is an ongoing project that includes 49 sentinel hospitals geographically 
dispersed throughout the USA and collects data on nosocomial bloodstream 
pathogens and their antimicrobial susceptibility patterns as well as clinical data [3, 
57, 59, 90]. The European Confederation of Medical Mycology (ECMM) executed 
a similar project in 106 institutions in seven European countries during 1997–1998 
[12, 91, 92]. 
Surveillance in intensive care unit (ICU) patients 
In 1970, the CDC established in the USA the oldest ongoing surveillance system, 
National Nosocomial Infections Surveillance (NNIS). A network of sentinel acute 
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care hospitals began to report all nosocomial infections to the NNIS on a voluntary 
basis [21, 67, 93, 94]. In addition to hospital-wide surveillance, three standardized 
protocols were initiated in the NNIS in 1986: the ICU, the high-risk nursery, and the 
surgical patient component. In 2005, the NNIS merged with two other healthcare 
surveillance systems at the CDC, The Dialysis Surveillance Network and the 
National Surveillance of Healthcare Workers, to establish the National Healthcare 
Safety Network (NHSN) [58, 95]. In Europe, a network for data on nosocomial 
infection rates in ICU patients was founded in 1994 by the Hospitals in Europe 
Link for Infection Control through Surveillance (HELICS), continued as part of the 
Improving Patient Safety in Europe project (IPSE), and transferred to the European 
Centre for Disease Prevention and Control (ECDC) in 2008 [69, 96–98]. During the 
1990s, two more limited surveillance programs for ICU patients were executed: the 
National Epidemiology of Mycoses Survey (NEMIS) in the USA and the European 
Prevalence of Infection in Intensive Care (EPIC) in Europe [40, 68, 99–102]. 
Surveillance for microbiological data
Two international programs on the occurrence and antimicrobial resistance patterns 
of yeast pathogens causing bloodstream or other infections (i.e., the SENTRY 
Antimicrobial Surveillance program and the ARTEMIS DISK Global Antifungal 
Surveillance Study) are ongoing. Participating centers are dispersed globally, whereas 
the isolated microbes are tested centrally, thus enabling the direct comparison of 
strains between different geographical areas [103–110]. 
2.1.6  Risk factors  
The list of reported risk factors for candidemia is extensive. Colonization with 
Candida spp. is considered a near-absolute requirement of candidemia (direct 
inoculation excluded), and the risk for infection may be related to the density 
and the extension of yeast colonization over time [111–114]. After colonization 
the main factor predisposing to candidemia is immunosuppression by disease or 
treatment, as in patients with haematological or solid malignancies, HIV patients, 
premature neonates, patients with extensive burns, and patients with transplants 
[47, 74, 115–121]. Thus, the patient groups at risk for candidemia have either severe 
underlying conditions impairing their host defences or are in need of invasive and 
intensive diagnostic procedures and medical or surgical treatments, or both. These 
predisposing factors may also evolve with changes in transplantation practices (e.g., 
new hematopoietic transplantation modalities and the technical complexity of 
surgery in liver transplantation) [122, 123]. 
Several prospective or retrospective cohort or case-control studies have 
identified multiple risk factors for candidemia in addition to prior colonization in 
different patient groups (ICU patients, neonates and patients with haematological 
or solid malignancies). Major risk factors include the use of central venous catheters 
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(CVCs); prolonged neutropenia; receipt of total parenteral nutrition (TPN), multiple 
bacterial antibiotics, or chemotherapy; gastrointestinal perforations and extensive 
abdominal surgery; renal failure or hemodialysis; and mechanical ventilation [35, 
40, 99, 113, 124–129]. Both neutropenia and chemotherapy-induced injury to 
the gut wall increase the risk for candidemia in patients with malignancies, while 
catheters, invasive procedures, and perforation or surgery of the gut wall are more 
important factors in the non-cancer settings. 
Because recognized risk factors are extremely common in the critically ill, 
clinical prediction rules have been created to select high-risk patients for candidemia 
[130–132] and the combinations of variables used include prior colonization, CVC 
or TPN, prior antibiotics, severe sepsis, hemodialysis, and major surgery. 
 Although rare, a study reported a genetic propensity for invasive Candida 
infections in humans: a homozygous point mutation in CARD9, which results in 
decreased numbers of Th17 cells (helper T-cells producing interleukin-17) in one 
family of five generations [133]. 
 
2.2 Diagnosing and typing methods for   
 candidemias 
The diagnostic strategy is to combine clinical signs, individual patient-related risk 
factors, and available laboratory data suggestive of Candida infection. While the 
gold standard for diagnosis is the detection and culture of causative yeast in clinical 
samples, new non-culture methods for earlier diagnosis, such as antigen assays 
and rapid PCR-based methods, are currently or will be in the future in clinical use. 
The investigation of outbreaks relies on molecular methods able to analyze strain 
relatedness. 
2.2.1  Primary diagnosis 
Culture
The fungal culture is the gold standard for diagnosis, but lacks sensitivity as up 
to 50% of blood cultures can be negative or become positive late in the course of 
infection [134, 135]. The detection of Candida spp. in blood culture systems depends 
on several variables, such as the volume of blood, the conditions of the medium and 
the atmosphere, the concentrations of yeast within the bloodstream, and the species 
of Candida in question [136]. Advances in blood culturing techniques to improve 
sensitivity and to reduce the time needed to obtain a positive culture include the 
development of lysis centrifugation tubes and specialized broth media as well as, 
importantly, the implementation of continuous-monitoring automated blood 
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culture systems (Bactec, Becton Dickinson, USA and BacT/Alert, Organon Teknika 
Corp., USA) [134, 136, 137]. 
Immunological and biological methods 
Non-culture or serological methods to detect candidemia and disseminated 
candidiasis are generally based on the detection of circulating antigens or fungal 
metabolites. The clinical usefulness of antibodies has been limited because of false-
positive results in patients with colonization and because immunosuppressed 
patients mostly produce low or undetectable antibody levels [134, 137]. 
Among the numerous potential target antigens, the highly immunogenic 
components of cell-wall antigens mannan and β-D-glucan are the most widely used 
and commercially available [134, 138, 139]. Mannan is the main component of the 
cell wall of Candida spp. and is rapidly cleared from the bloodstream, thus requiring 
regular sampling. Circulating mannan antigens detected with immunoassay, 
performed in parallel with antimannan antibody tests, have yielded a high sensitivity 
of 80% and a specificity of 93% in the diagnosis of candidemia and disseminated 
candidiasis [138]. β-D-glucan is part of the outer wall of many pathogenic fungi 
and is also ubiquitous in the environment, which may generate false-positive results 
[137, 138]. Most medically important Candida spp. (except C. krusei and C. glabrata) 
produce a metabolite known as D-arabinitol, which can be measured in serum and 
urine [134, 140]. The clinical significance of D-arabinitol detection is limited in 
guiding the initiation of antifungal therapy [141]. 
Molecular methods
Molecular methods targeting fungus-specific nucleic acids have been applied directly 
to clinical materials or to the contents of blood culture bottles to circumvent the 
time needed for culture and to increase the sensitivity of detection [134]. The use of 
specific oligonucleotide probes enables identification of an organism to the species 
level and can theoretically detect mixed fungal infections accurately. The amount of 
target yeast DNA available in clinical samples is typically very low, thus techniques 
used for detection necessarily rely on amplification [142]. These techniques include 
polymerase chain reaction (PCR) and nucleic acid sequence-based amplification 
(NASBA). Currently, molecular strategies complement conventional methods and 
are used only in specialty laboratories. 
Target sequences in PCR-based methods may be either species-specific, 
Candida-genus specific, or universal panfungal sequences. The ribosomal RNA 
(rRNA) gene most often serves as the target sequence, with sensitivity ranging from 
78% to 100% for Candida infections while specificities vary [137, 142]. Nested PCR 
increases the sensitivity and specificity of detection, but at the expence of amplifying 
the occurrence of false-positive results [142]. Real-time PCR allows for rapid 
detection of the production of amplicons [142]. NASBA is a specific and sensitive 
RNA amplification technique capable of detecting six various Candida species. 
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Compared to PCR, NASBA detects only living yeast cells and needs no thermal 
cycling instrument, but is more expensive [142].  
   
2.2.2  Species identification 
Most yeasts are identified on the basis of carbohydrate assimilation and fermentation 
tests along with their macroscopic and microscopic morphologic features on 
specialized media [134, 137]. Rapid and less laborious commercially available methods 
have been developed, perhaps the most convenient consisting of fully automated 
system that evaluates an optical signal generated by individual biochemical reactions 
contained within a variety of microbe identification cards (VITEK 2, bioMérieux, 
Inc. Hazelwood, MO) [143, 144]. The addition of chromogenic substrates to the agar 
medium allows the direct detection of spesific enzymatic activities characteristic of 
selected species of Candida by their color and colony characteristics [145].  
Molecular methods based on PCR, as described for the primary diagnosis of 
candidemia, also allow for species identification. Fluorescent in-situ hybridization 
(FISH) may serve to detect yeasts without the need for a pure culture [134, 142]. 
Although FISH is probably less sensitive and requires more time than PCR-based 
methods, it may be more economical as only positive samples are examined. Novel 
peptide nucleic acid (PNA) FISH requires only 2.5 hours after a blood culture is 
designated positive and is able to differentiate C. albicans from non-albicans Candida 
spp. (sensitivity and specificity 100%) as well as from C. dubliniensis [137, 142].
2.2.3  Susceptibility testing 
Antifungal choice is based primarily on Candida spp. identification, but antifungal 
susceptibility tests play an increasingly important role in selecting which agent to 
use. Susceptibility testing also allows for resistance surveillance and comparison 
of the in vitro activity of new and existing agents. Methods used for susceptibility 
testing of yeasts include disc diffusion, agar dilution, and broth dilution procedures. 
Numerous in vitro factors such as media, buffer, inoculum, incubation and end point 
criteria may significantly affect the results [146]. 
In the USA, the Clinical and Laboratory Standards Institute (CLSI; formerly 
the National Committee on Clinical Laboratory Standards, NCCLS) has developed 
standard methods based on broth dilution and disc diffusion to test the susceptibility 
of yeasts [147, 148]. Althoug quality control and minimal inhibitory concentration 
(MIC) breakpoint criteria have been established for most antifungals, there is a 
concern that these methods fail to distinguish amphotericin B-resistant strains. 
[137, 146–148]. In Europe, the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) has developed a standardized broth dilution method for 
the susceptibility testing of yeasts with MIC breakpoint criteria established for 
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fluconazole and voriconazole [149]. Despite of methodological differences, 
these methods generate rather similar and comparable results [150]. Interpretive 
categories differ, however, between CSLI and EUCAST, as CSLI categorizes these as 
susceptible, susceptible-dose dependent, and resistant, while EUCAST assigns only 
susceptible or resistant categories. 
Because these standardized methods are time consuming and laborious, more 
convenient techniques have been developed for routine susceptibility testing. The 
Etest method (AB Biodisk) is widely used and yields accurate, reproducible, and 
quantitative MIC results, but the values tend to be slightly higher than with broth 
dilution methods [151, 152]. Several other methods are commercially available as 
well as fully automated system that determines yeast growth spectrophotometrically 
[146, 150, 153–155]. 
2.2.4  Epidemiological typing methods for candida   
 infections 
Molecular methods enable assessment of the interrelatedness of clinical isolates 
and thus facilitate the tracing of sources and routes of transmission of infection 
outbreaks. A vast array of molecular typing methods is available, based on either 
nonamplifying techniques or those using DNA amplification by PCR, a summary 
of which appears in Table 1. All systems require a pure culture of each isolate, yeast 
cell lysis, DNA extraction, and the use of electrophoresis to separate DNA fragments 
into patterns (fingerprints), which are then visualized by staining or by hybridizing 
with labelled probes [156]. 
Most fungal species display chromosome-length polymorphisms, which can 
be analyzed by electrophoretic karyotyping (EK) [142, 156]. The development of 
pulsed-field gel electrophoresis (PFGE) allows the separation of even extremely large 
DNA fragments and allows for high reproducibility and discriminatory power, thus 
making it currently the method of choice in most outbreak investigations [156]. In 
restriction enzyme analysis (REA) and in restriction fragment length polymorphism 
(RFLP), DNA is cleaved by selected endonucleases into small fragments, which 
are then separated with electrophoresis. RFLP is rapid, easy, and inexpensive, 
but restriction patterns are very complex and difficult to compare [142]. For 
easier comparison, separated fragments can be transferred onto a membrane and 
hybridized with a labeled probe [142, 156]. 
Random amplified polymorphic DNA (RAPD), also referred to as arbitrarily 
primed PCR (AP-PCR), uses arbitrarily chosen primers to amplify nearly 
homologous sequences of genomic DNA. Strains are then differentiated by 
determining the characteristic number and size of the amplified fragments with 
electrophoresis [142, 156]. While RAPD is easy, technically simple and fast, minor 
differences in experimental conditions can result in different profiles, thus reducing 
reproducibility. Amplified-fragment length polymorphism (AFLP) based on the 
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selective amplification of a subset of DNA fragments generated by restriction 
endonucleases, then separated by gel electrophoresis and analyzed [156]. AFLP is 
not only a highly reproducible and robust method, but is also easier to read than 
RFLP. Multilocus sequence typing (MLST) is based on the nucleotide polymorphism 
of internal fragments of six to eight independent chromosomal genes [157]. MLST 
schemes have been developed for five Candida species, and maintained as an open 
platform.
TABLE 1. Comparison of performance characteristics of epidemiological typing methods for 
Candida species (modified from [142, 156]).
Advantages Disadvantages Time 
required 
(days)
Comments
Non-amplified
EKa with PFGEb high reproducibility
high discriminatory 
power
laborious
expensive equipment
3–5 widely 
used
REAc, RFLPd 
(conventional 
electrophoresis 
or PFGEb)
rapid
easy
inexpensive
complex banding 
patterns
laborious
2
Amplified
RAPDe or 
AP-PCRf
high discriminatory 
power
universally applicable
rapid
easy
inexpensive
lack of reproducibility 1 widely 
used
AFLPg reproducible
high discriminative 
power
automation
laborious
expensive
needs expertise
2
MLSTh high discriminative 
power
reproducible
rapid
technically 
demanding
expensive
applicable to 5 
Candida species
2
aEK = electrophoretic karyotyping; bPFGE = pulsed-field gel eletrophoresis; cREA = restriction 
enzyme analysis; dRFLP = restriction fragment length polymorphism; eRAPD = random amplified 
polymorphic DNA; fAP-PCR = arbitralily primed polymerase chain reaction; gAFLP = amplified 
fragment-length polymorphism; hMLST = multilocus sequence typing.
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2.3 Epidemiology of candidemia 
2.3.1  Incidence 
The incidence of candidemia has mostly been studied in population-based or in-
hospital settings. Although population-based data are representative of the whole 
population living in the area studied and contribute to a more comprehensive data 
set, inclusion of both inpatients and outpatients, and the lack of selection bias that 
is inherent in tertiary care hospital-based studies, they are expensive and laborious, 
and so are essentially limited to a specific geographical area and time period. Sentinel 
surveillance programs are more flexible, however, and allow sampling of consecutive 
episodes of infection from a large number of institutions over a broad geographical 
area, and for a prolonged period of time [158].
Population-based studies
A summary of population-based studies appears in Table 2. The first population-
based studies reported high average annual incidences between 8.0–7.3 per 100,000 
population in selected urban areas in the USA during 1992–1993 [83, 84]. Subsequent 
studies observed great variation in incidences between urban and rural areas (24 vs. 
7.0–6.0 per 100,000 population) [23, 82]. Also, incidence rates in Canada differed 
across separate areas and increased over time in Calgary [11, 159]. In Australia, 
the annual incidence rate was low (1.8 per 100,000 population) with wide variation 
between different parts of the continent [160]. 
In Iceland, during 26 years of observation, the annual incidence was low but 
rose; in Norway, during 13 years of observation, annual incidence remained low and 
constant at 2.4 per 100,000 population [17, 86, 161]. In Denmark, however, incidence 
rates have been much higher: 11 per 100,000 population, during the 2000s [85, 162]. 
Elsewhere in Europe, reported annual incidence rates have been somewhat higher 
than in Scandinavia, but lower than in the USA [87, 89]. In the UK, the incidence 
of candidemia increased during 2004–2007, but considerable differences have been 
noted between different areas, with rates in Northern Ireland being much higher 
than in Wales or England [87]. 
The highest age-specific incidence rates have been observed in infants <1 year 
of age 75 per 100,000 population in the USA and in Canada, and somewhat lower 
in Europe, 10.3–38.8 per 100,000 population [11, 17, 83, 85, 86, 89]. The incidence 
is low in patients aged ≥1–40 years but subsequently increases with advancing age 
hence the annual incidence in the range of 7.4–36.9 per 100,000 population in 
patients >65 years of age [17, 83, 85, 86, 89]. Male dominance in all age groups is 
common globally, though not constantly [11, 23]. 
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TABLE 2. Summary of population-based studies reporting annual incidences of candidemias and the proportion 
of non-C. albicans species.
Country/area Time 
period
Catchment
population
Incidence 
per
100,000 
population
Proportion of 
non-C. albicans 
spp.
Reference Remarks
USA/Atlanta, 
San Francisco
1992–1993 5.34 million 8.0 44–51% [83]
USA/California 1992–1993 2.94 million 7.3 not available [84]
USA/ 1998–2000 4.7 million 10.0  55% [23]
   Baltimore 24.0
   Connecticut 24.0
USA/Iowa 1998–2001 not available 6.0 
(5.6–6.8*)
not available [82]
Canada/ 1992–1994 2.22 million 3.3 31% [159]
   Hamilton 5.1
   Ottawa 1.2
   Manitoba 3.5
Canada/Calgary 1999–2004 ~1 million 2.8 49% [11] 
Australia 2001–2004 not available 1.8 53% [160] 2 of 52 
laboratories 
missing 
Norway 1991–2003 ~4.3million 2.4 
(2.0–3.3*)
30% [17] 
Iceland 1980–1999 0.285 million 1.4–4.9* 32% [86]
Iceland 1991–2006 ~0.281 million 3.3–5.8* 38% [161] 
Denmark 2003 2.8 million 11.0 35% [162]
Denmark 2004–2006 3.5 million 10.4 38% [85]
Spain/Barcelona 2002–2003 3.9 million 4.3 49% [89]
UK 2004–2008 not available 3.2–3.6* 35–36% [87] voluntary 
reporting
   England 3.1–3.5*
   Wales 2.7–3.1*
   Northern 
   Ireland
5.0–6.8*
*Range per year. 
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In-hospital studies
As Table 3 shows, candidemia rates vary according to the characteristics of the 
patient population considered and the type of institution. The comparison of 
rates is complicated by differences in calculated rates (i.e., per patient days or per 
admissions or discharges). Incidence rates are lower in general hospitals than in 
tertiary care centers (TCCs), and are probably best shown as rates per 1,000 patient 
days (incidence densities). 
In the USA, the incidence rates for candidemia and disseminated candidiasis 
rose considerably during the 1980–1990s both in general hospitals and in TCCs, and 
have remained stable, 0.02 per 1,000 admissions, during the 2000s [1, 2, 163–165]. 
In Europe, average annual incidence rates have varied between 0.02–0.07 per 1,000 
patient days or 0.2–0.5 per 1,000 discharges in general hospitals during the 1990–
2000s [12, 89, 92, 166–169]. In 5 TCCs in the Netherlands during 1987–1995, annual 
incidence rose over time from 0.03 to 0.07 per 1,000 patient days, while in 17 TCCs in 
Switzerland the annual incidence remained stable 0.05 per 1,000 patient days during 
1991–2000 [5, 65]. In Europe, many of the reports are from single centers over a 
short period of time and while some of the studies covering a longer period of time 
have observed the increase in incidence [170], others have not [14, 75, 171]. Only 
one center reported a decrease in incidence from 0.2 to 0.1 per 1,000 patient days 
during 2001–2005 [172]. In Australia (Queensland), the average annual incidence 
rose 7.6-fold (from 0.007 to 0.05 per 1,000 patient days) in general hospitals and 
2.9-fold (from 0.03 to 0.1 per 1,000 patient days) in adult TCCs during 1999–2008 
[173]. At 0.4 per 1000 patient days, the observed average incidence of candidemia 
has been higher in TCCs in Brazil than both in the USA or Europe [174, 175]. On 
the other hand, in Taiwan, in one TCC, the incidence of candidemia has been rising 
constantly during 1981–2000 [176]. 
The incidence of candidemia is higher in ICU patients than in general wards, 
but rates vary considerably between institutions and according to predominant type 
of patients receiving care in the ICU (i.e., neonatal, pediatric, and adult medical or 
surgical ICU). In neonatal ICUs (NICUs) the observed rates have been high, 12.3 per 
1,000 admission or 0.6 per 1000 patient days in the USA [40, 100, 118]. In Europe, the 
incidence rates among NICU patients have been lower, 11 per 1,000 admissions or 
0.03 per 1,000 patient days [88, 172]. The reported incidence rates in pediatric ICUs 
(PICUs) have been in the same range (0.02 per 1,000 patient days or 0.6 per 1000 
CVC days) [5, 15]. Reported incidence rates in adult ICU patients have been high, 1 
per 1,000 patient days or 9.8 per 1000 admissions in the USA, but during 1989-1999 
a decreasing rate was observed, varying between the 0.7–0.5 per 1000 CVC days [15, 
100]. In Europe the rates among adult ICU patients have varied greatly from 2.0 to 
6.7 per 1,000 admissions or from 0.03 to 0.2 per 1,000 patient days [5, 14, 172, 177–
179]. In Australia and Taiwan, the reported incidences among adult ICU patients 
have been similar to Europe [5, 14, 172, 173, 177–180]. Reported annual incidences 
for candidemia in cancer centers have varied from 5.2 to 6.0 per 1,000 admissions 
[13, 181]. In hematology units reported incidences have varied from 0.05 to 0.9 per 
1,000 patient days [9, 168, 172, 178]. 
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TABLE 3. Summary of in-hospital studies reporting incidence rates and the proportion of non-C. albicans species. 
Country/Type 
of hospital
Number of
hospitals
Time period Incidence rate/ Proportion of 
non-C. albicans 
spp.
Case fatalityb Reference Remarks
1,000 patient days 1,000 admissionsa
General hospitals
USA/NHDSc 1980–1989 0.01–0.15c NAe 45% [164] disseminated 
candidiasisf
USA/NNISg 1980–1989 0.3 NA NA [163]
USA/NHDSc 1996–2003 0.2 NA NA [2] disseminated 
candidiasisf
Norway 1991–1996 0.03 0.2 34% NA [169]  ~96% 
candidemias
Israel 14 1994 0,4 46% 22% [167] all candidemias
France 25 1995 0.04 0.3 47% NA 168] nosocomial ~70%
Europe/ECCMh 106 1997–1999 44% 38% [12] all candidemias
   France 18 0.2 (0.04–1.3l) NA
   Germany/
   Austria
5 0.03 (0.01–0.05l) NA
   Sweden 6 0.3 (0.1–1.4l) 33% 31% [91]
Italy 32 1997–1999 0.04 0.4 42% 35% [92] nosocomial 97%
France 1998–2001 0.3 50% NA [166] all candidemias
Spain 14 2002–2003 0.07 0.5 49% 44% [89] all candidemias
Australia 167 1999–2008 0.05 (0.02–0.07d) 0.15 55% NA [173] all candidemias
Australia 40 2001–2004 0.2 53% NA [160] nosocomial 82%
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Country/Type 
of hospital
Number of
hospitals
Time period Incidence rate/ Proportion of 
non-C. albicans 
spp.
Case fatalityb Reference Remarks
1,000 patient days 1,000 admissionsa
Tertiary care centers
USA/NNISg 1980–1989 0.4–0.6i NA NA [163]
USA 1 1983–1986 0.9 39% 57% [1]
USA 1 1987–1994 0.04–0.10d 49–23% NA [165]
Netherlands 5 1987–1995 0.03 (0.03–0.07d) 33% NA [65] all candidemias
Spain 1 1988–2000 0.6 49% NA [14] nosocomial
Switzerland 17 1991–2000 0.05 34% NA [5]
Italy 1 1992–1997 0.1 (0.10–0.12d) 46% 45% [16]
Belgium 1 1994–2004 0.09 (0.06–0.14d) 37% NA [182]
UK 2 1995–2001 0.3 (0.2–0.4d) 36% 35% [170] nosocomial
France 9 1995 0.05 0.4 49% NA [168] nosocomial ~70%
Spain 1 1995–1997 0.76 54% 44% [183] all candidemias
Spain 1 1995–1999 0.81 56% 45% [171] all candidemias
Ireland 1 1999–2003 0.07 (0.06–0.08d) 0.5 (0.4–0.6d) 50% 40% [184] all candidemias
Belgium 1 2001–2005 0.2 (0.2–0.1d) 41% NA [172] nosocomial 
fungemia
Portugal 1 2004 2.0 NA 39% [185] all fungemias
Taiwan 1 1981–2000 0.08–0.3d 40–60% NA [176] nosocomial
Canada 3 1992–1996 0.05 (0.2–0.8i) 46% 46% [186] all candidemias
Australia 1 1992–1999 0.05 0.27 47% 45% [9] nosocomial
Australia 8 1998–2008 0.6 (0.03–0.09i) 55% NA [173] all candidemias
Brazil 4 2002–2003 1.7 (1.5–2.0i) 62% 61% [174] nosocomial 89%
Brazil 11 2003–2004 0.4 (0.2–0.5i) 2.5 (1.5–5.3i) 59% 54% [175] all candidemias
 aadmissions or discharges; b within 30 days, during hospitalization or not defined; cNHDS = National Hospital Discharge Survey; drange by year; eNA = not 
available; fdischarge data; gNNIS = National Nosocomial Infections Surveillance; hECMM = European Confederation of Medical Mycology; irange by hospital.
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2.3.2  Causative species 
The most abundant causative species, by far, is C. albicans (Tables 2 and 3), but 
many centers reported a worldwide shift during the 1990s towards non-C. albicans 
species [13–15, 23, 65, 83, 85]. Both population-based and in-hospital studies have 
reported this shift in causative species, yet many studies have observed no change 
in causative species over time [5, 17, 182]. International surveillance studies have 
observed marked geographical variation in the distribution of causative species of 
candidemia, with C. glabrata ranking second and C. parapsilosis third in the USA; 
in Canada and Europe C. parapsilosis ranked second before C. glabrata, and in Latin 
America C. glabrata was rarely isolated [22, 103, 104]. The species distribution also 
differs by demographics and the type of the patient population observed, as C. 
parapsilosis is most abundant in neonates, C. glabrata is observed mostly in adults 
and older age groups and C. krusei in cancer patients [12, 13, 82, 118, 160].
2.3.3  Outbreaks in specific hosts
Outbreaks of candidemia stemming from a single strain are uncommon, but 
several reports have described nosocomial clusters in different patient populations. 
Horizontal transmission from patient to patient or acquisition from the hospital 
environment in ICUs and the bone marrow transplant unit has been documented for 
C. albicans, C. glabrata, and C. parapsilosis strains [44–46, 187–189]. The principal 
mechanism of transmission is most probably indirect contact via HCWs hands, but 
other mechanisms include the contamination of intravenous fluids and medical 
devices [49, 190–192]. 
Outbreaks in neonates
C. parapsilosis has caused several nosocomial clusters of candidemia in neonates. The 
longest observation period has been 12 years, with the domination of a single strain 
of C. parapsilosis in one NICU, while most studies report several strains (genotypes) 
responsible for a short outbreak [193–196]. In one study, the source of transmission 
was liquid glycerine suppositories, and another identified the mecanism as the hand 
carriage of causative strains but the sources have largely remained elusive [193, 196]. 
C. albicans has also caused outbreaks of candidemia in neonates, and one study 
reported hand carriage of the causative strain [197–199]. Two studies have attributed 
outbreaks in neonates to several Candida spp. [200, 201]. Another study associated 
an outbreak with the use of topical petrolatum ointment, while yet another study 
identified retrograde medication syringes contaminated by the causative strain.
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Outbreaks in critically ill and surgical patients 
Candidemia outbreaks in critically ill patients have mostly been caused by C. 
parapsilosis [202–205]. The cause of these outbreaks has probably been multifactorial, 
as seriously ill patients often require invasive ventilation and monitoring, and thus 
frequent contact with HCWs, which facilitate the cross-transmission of causative 
yeasts and magnifies the impact of lapses in hand hygiene [202]. One study identified 
hyperalimentation infusion fluid as a common source of infection [205]. C. albicans 
outbreaks in critically ill patients have been associated with hand carriage of the 
causative strain [206, 207]. One report documents an outbreak caused by a single 
strain of C. rugosa in a burn unit [208]. C. parapsilosis has been implicated in two 
candidemia outbreaks consisting of five and four patients, respectively, in patients 
with prosthetic valve surgery [209, 210]. In the first outbreak in 1984, C. parapsilosis 
was cultured from cardiac bypass equipment, while the second outbreak probably 
stemmed from frequent glove tears during surgery, thus facilitating transmission 
of the yeast to patients. One report revealed the persistence of a single C. albicans 
strain for four years in a surgical ward causing eight candidemias [211]. Short BSI 
outbreaks caused by C. albicans in surgical patients have been associated with 
intravenous fluids or anesthetic agents [212, 213]. 
Outbreaks in patients with hematological or solid malignancies 
Several outbreaks among haematological or cancer patients have been attributed to 
C. parapsilosis and associated with hand carriage of the causative strain in HCWs [41, 
214–216]. One study reported an extensive C. krusei outbreak in the Netherlands 
consisting of 13 patients with candidemia and another 26 patients with colonization 
[217]. The outbreak was polyclonal, but the same genotype of C. krusei was identified 
in 25 out of the 39 patients, while all environmental cultures were negative. A cluster 
of 12 invasive C. krusei infections was detected within 9 months in a hematological 
unit, but nosocomial spread could not be shown [218].  
2.3.4  Outcome
The case fatality ratio or rate (i.e., all-cause or crude mortality) is the ratio of the 
number of deaths from candidemia divided by the number of candidemia cases, 
expressed as a percentage [50]. Mortality rate is the number of deaths in candidemia 
patients divided by the number of individuals in a defined population during a certain 
period of time, such as a year (annual mortality rate), but the term is still often used 
to replace case fatality in the published literature. Reported case fatality ratios differ 
in terms of the observation period they use, thus complicating comparisons. Most 
report in-hospital crude mortality, but case fatalities over one week (7 days) and 
one month (28 to 30 days) are also common in the published literature. Attributable 
mortality refers to deaths directly related to candidemia in contrast to all-cause 
mortality. 
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Studies have reported high all-cause mortality among candidemia patients, 
ranging from 22% to 45% in a series of general hospitals and from 31% to 61% in a 
series of TCCs (Table 3). The case fatality ratios of candidemia have remained high 
during the past three decades despite new antifungals: only one study reported a 
significant decrease over time from 59% during 1980–1984 to 27% (per 30 days) 
during 1995–1999 in Iceland [219]. In matched cohort and case-control studies, the 
in-hospital mortality rate attributable to candidemia has varied between 15–49% in 
hospitalized patients in general, 5–31% in ICU patients, and 10–12% in pediatric 
patients and neonates [1, 6, 8, 75, 76, 78, 220]. The considerable variation in figures 
may exist because, although mortality associated with candidemia is high, this 
condition usually affects patients with severe underlying disease and thus a grim 
prognosis.
The risk factors for death among patients with candidemia include age ≥70 years, 
treatment for hematological or solid tumor, and candidemia caused by C. glabrata, 
C. krusei, or C. albicans [12, 16, 91, 92, 121, 167, 171, 183]. Among hematological 
and cancer patients, additional factors include prolonged neutropenia, allogeneic 
bone marrow transplantation, septic shock, and lack of antifungal prophylaxis, while 
high APACHE II scores in critically ill contribute to high crude mortality [10, 121, 
181, 183, 221]. Regarding treatment, failure to promptly remove CVC and delay in 
the initiation of adequate antifungal treatment have increased crude mortality in 
candidemia patients [75, 115, 222–224]. 
2.4 Prevention and treatment strategies  
2.4.1  Preventive measures and prophylaxis 
Given the substantial excess mortality due to candidemia and the difficulties 
encountered in the early diagnosis and administration of effective antifungal 
treatment, the focus has been on prevention [24, 225]. Three low-tech strategies 
should be the primary approach to reducing the burden of nosocomial candidemia: 
improved hand hygiene, optimal catheter care, and prudent antimicrobial use [2, 
24, 226]. Reducing the duration of neutropenia by using hematopoetic growth 
factors and curtailing mucosal damage resulting from herpes simplex infections are 
suggested options, but both require further study [226]. Considering that candidemia 
arises from endogenous sources, a rational preventive measure would be to reduce 
colonization with chemoprophylaxis. In ICU patients, a nosocomial setup with a 
high level of activity point to difficulties in implementing infection control practices: 
thus decreasing hand contamination of HCWs and strict hygienic practices in using 
invasive monitoring would be best methods. Alcohol-based hand rubs decrease 
hand contamination more effectively than use of soap and water [227, 228]. 
Antifungal prophylaxis should always be considered secondary to the standard 
infection control strategies and should be applied only when the rate of candidemia 
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remains elevated despite the assiduous application of these measures [24]. Antifungal 
prophylaxis has proved effective in decreasing colonization and invasive candidiasis, 
and at least a trend towards a reduction in associated mortality among neutropenic 
patients has been observed, while the benefits and cost-effectiveness of this strategy 
in nonneutropenic patients treated in ICU remain incompletely defined [2, 24, 225, 
229–239]. Also, the issue of selecting for fluconazole- or triazole-resistant strains of 
C. glabrata and C. krusei should be addressed locally when choosing antifungals for 
use in prophylaxis.
The Infectious Diseases Society of America (IDSA) has published guidelines for 
using antifungal prophylaxis in different patient populations, including solid-organ 
recipients, hematological patients, the critically ill, and neonates (Table 4), along with 
the grading of evidence (Table 5) [229]. The Immunocompromised Host Society 
(ICHS), together with the European Organisation for Research and Treatment of 
Cancer (EORTC), the European Group for Blood and Marrow Transplantation 
(EBMT), and the European Leukemia Net have all contributed to the development 
of the European guidelines (the 3rd European Conference on Infections in Leukemia, 
ECIL) for prophylaxis and the management of bacterial and fungal infections in 
hematological patients (Table 4) [240]. Both of these guidelines regard antifungal 
prophylaxis in the primary prevention of invasive yeast and mould infections as 
the standard of care in acute leukemia patients and allogeneic stem cell transplant 
recipients during the neutropenic phase. Antifungal prophylaxis is recommended 
postoperatively for high-risk liver, pancreas, and small-bowel transplant recipients 
[229]. For critically ill adult patients, prophylaxis is recommended only to high-
risk patients (e.g., patients with gastrointestinal surgery, CVCs, broad-spectrum 
antimicrobial agents, and multiple sites of candida colonization) in units with a high 
incidence of invasive candidiasis [229, 241]. In nurseries at high risk for invasive 
candidiasis, fluconazole prophylaxis is recommended to neonates with birth weights 
<1,000g.  
2.4.2  Preemptive and empiric treatment strategies 
Lack of specific clinical findings and slow, insensitive diagnostic methods complicate 
the early recognition and treatment of candidemias, while fungal BSIs have been 
shown to have some of the highest rates of inappropriate initial therapy and hospital 
mortality among all examined etiological agents of BSI [2, 224]. These factors have 
prompted the development of empirical and preemptive strategies for the treatment 
of candidemia. Different definitions exist, but most commonly preemptive therapy 
refers to the early treatment of infection with the use of clinical, laboratory, or 
radiological surrogate markers of disease in a high-risk host before clinical signs 
and symptoms of overt disease develop. Empirical therapy refers to the treatment of 
high-risk hosts who exhibit signs and symptoms of the disease, even in the absence 
of positive cultures or other evidence of disease [2, 242]. 
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Empirical antifungal therapy is the standard of care among neutropenic 
cancer patients with persistent fever despite the administration of broad-spectrum 
antimicrobial agents [229, 240]. Preemptive antifungal therapy triggered by a 
radiological or serum marker has been proposed as a cost-effective substitute for 
empirical antifungal therapy in febrile, neutropenic patients [243]. Early initiation of 
antifungal therapy may reduce morbidity, mortality, and length of stay in critically ill 
patients, but the widespread use of these agents must be balanced against the risk of 
toxicity, costs, and the emergence of resistance. Empirical antifungal therapy should 
also be considered in critically ill patients with risk factors for invasive candidiasis 
and no other known cause of fever [229, 241, 244, 245]. 
CVCs should be removed when candidemia is documented, if logistically 
feasible. The data supporting removal of CVCs are strongest among non-neutropenic 
patients and show that catheter removal is associated with shorter duration of 
candidemia and reduced mortality in adults and neonates [229]. The data on catheter 
removal in neutropenic patients with candidemia are less compelling [246, 247]. 
TABLE 4. Summary of published guidelines for the use of antifungal prophylaxis in different 
patient populations [229, 240]
Patient group at risk Recommendation Duration
IDSA*
Patients with 
chemotherapy induced 
neutropenia
fluconazole 400mg (6mg/kg) daily (AI)
posaconazole 200mg 3 times per day (AI)
caspofungin 50mg daily (BII)
oral itraconazole 200mg daily (AI)
During induction 
chemotherapy for 
the duration of 
neutropenia
Allogeneic stem cell 
transplant recipients
fluconazole 400mg (6mg/kg) daily (AI)
posaconazole 200mg 3 times daily (AI)
micafungin 50mg daily (AI)
During the period of 
risk of neutropenia
Solid-organ transplant 
recipients   
   Liver (high-risk) (AI)
   Pancreas (BII)
   Small bowel (BIII)
fluconazole 200-400mg (3–6mg/kg) daily
liposomal amphotericin B 1–2mg/kg daily
≥7–14 days 
postoperatively
ICU**patients
   Adult high-risk 
   patients in units 
   with high 
   incidence of 
   invasive 
   candidiasis (BI)
   Neonates with birth 
   weight <1000g
fluconazole 400mg (6mg/kg) daily 
fluconazole 3–6mg/kg twice weekly (AI)
2   Review of the literature
39Research 54/2011
National Institute for Health and Welfare
Epidemiology of Candidemia in Finland
Patient group at risk Recommendation Duration
ECIL***
Patients with 
induction 
chemotherapy of 
acute leukemia
fluconazole 50–400mg daily iv/oral (CI)
itraconazole oral solution 2.5mg/kg twice 
daily (CI)
posaconazole 200mg 3 times daily (AI)  
polyene iv (CI)
aerosolized amphotericin B+ oral 
fluconazole (BI)
candins iv: insufficient data
Allogeneic stem cell 
transplant recipients 
fluconazole 400mg daily iv/oral
itraconazole 200mg iv followed by 
oral solution 200mg  twice daily (BI)      
micafungin 50mg daily (CI)
polyene iv (CI)
voriconazole 200mg twice daily 
(provisional AI)
aerosolized lisomal amphotericin 
B+fluconazole (BII)
posaconazole oral: no data
During the 
neutropenic phase
Allogeneic stem cell 
transplant recipients
fluconazole  400mg daily iv/oral (CI) 
itraconazole 200mg iv followed by oral 
solution 200mg twice daily (BI)
posaconazole 200mg 3 times daily (AI)
polyene iv (CI)
voriconazole 200mg twice daily oral 
(provisional AI)
aerosolized liposomal amphotericin 
B+fluconazole and candins iv: insufficient 
data
During graft-versus 
host disease phase
*IDSA = Infectious Diseases Society of America; ICU = intensive care unit; ***ECIL = European 
Conference on Infections in Leukemia.
Table 4 continues
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TABLE 5. The grading system for ranking recommendations in clinical guidelines [229, 240].
Category; grade Definition
Strength of recommendation
A Strong evidence for efficacy and substantial clinical 
benefit. 
Strongly recommended
B Strong/moderate evidence for efficacy, but only limited 
clinical benefit. 
Generally recommended
C Insufficient evidence for efficacy; optional
Quality of evidence 
I Evidence ≥1 properly randomized, controlled trial 
II Evidence from ≥1 well-designed clinical trial without 
randomization; 
or cohort of case-controlled analytic studies (preferably 
from >1 center); 
or from multiple time-series; 
or from dramatic results from uncontrolled experiments
III Evidence from the opinions of respected authorities, 
based on clinical experience, 
descriptive studies, or reports of expert committees
2.? Candidemia in Finland in lig ht of previous  
 studies 
A summary of previous Finnish studies of candidemia appears in Table 6. Candidemias 
accounted for 4% of nosocomial BSIs in a surveillance study of hospitalized patients, 
although the proportion was higher (6%) in pediatric patients [64, 248]. During 
1980s yeasts (95% Candida spp.) were detected in 0.2% of all blood samples taken for 
culture, and during 1989-1991, candidemia was observed in 1.9% of adult patients 
who underwent abdominal surgery [249, 250]. Candidemia has also been reported 
in 1.3% and 0.3% of adult allogeneic or autologous stem cell transplant recipients, 
respectively, while Candida spp. accounted for 0.4% of episodes of neutropenic 
fever among adults treated for acute myeloid leukemia [251–253]. Fluconazole 
prophylaxis was instituted in only 10% of autologous stem cell recipients. As for 
children, candidemia occurred in 3.4% of stem cell transplant recipients, 70% of 
whom received systemic antifungal prophylaxis [254]. Two studies which specially 
evaluated antifungal prophylaxis and which were executed in hematological patients, 
both found a low rate of candidemia and no evidence of a trend towards non-C. 
albicans spp [235, 255]. 
Reports from Finland have identified two nosocomial clusters of candidemia 
caused by Candida spp. A C. parapsilosis outbreak in one NICU, caused by a single 
strain with decreasing susceptibility to fluconazole, has persisted since 1987 [194, 
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256]. A cluster of invasive C. krusei infections occurred in twelve patients, among 
whom six candidemias were investigated in a hematological ward [218]. This cluster 
was caused by several C. krusei strains: the nosocomial spread could not be shown. 
Hepatosplenic candidiasis was studied extensively among adult leukemia 
patients during 1980–1993 in Finland, while candidemia was diagnosed in only six 
patients [257]. 
TABLE 6. Summary of Finnish studies on candidemias in different patient populations
Study population Number of 
infections/
patients/blood 
cultures
Hospitals Years Proportion of 
candidemias
Reference
Nosocomial BSIa in 
Finnish Hospitals
1,477
Selected 
hospitals/ SIROb
1999–2000 4% [64]
Nosocomial BSIa in 
children
739 HCAc 1999–2006 6% [248]
Adult febrile patients 
<24h after abdominal 
surgery
107
Turku University 
Hospital
1989–1990 1.9% [250]
Adult allogeneic 
transplant recipients
685 HUCHd 1983–2002 1.3% [252]
Adult autologous stem 
cell recipients
1,188
Six Finnish 
transplant 
centers (nation-
wide)
1990–2001 0.3% [253]
Episodes of neutropenic 
fever in adult AMLe 
patients
280
Kuopio University 
Hospital
1996–2005 0.4% [251]
Pediatric stem cell 
transplant recipients
148 HCAc 1986–1996 3.4% [254]
Pediatric hematology 
patientsf 
98 HCAc 2000–2002 1% [255]
Adult acute leukemia 
patientsg
1,089 HUCHd 1978–2004 8.7% vs 1.6% [235]
Blood cultures 35,618
Turku University 
Hospital
1981–1986 0.2% [249]
aBSI = blood stream infection; bSIRO = Finnish Hospital Infection Program; cHCA = Hospital for Childrean and 
Adolescents; dHUCH = Helsinki University Central Hospital; eAML = Acute myeloid leukemia; fprophylaxis with 
itraconazole oral solution 5mg/kg daily or fluconazole 5–8mg/kg daily oral/iv; gprophylaxis with fluconazole 
400mg daily since the year 2000.
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3	 Aims	of	the	study
 
The purpose of this study was to provide comprehensive data on the population-
based incidence and outcome of Candida bloodstream infections in Finland. 
With special emphasis on the largest tertiary care centre in Finland, the Helsinki 
University Central Hospital (HUCH), we assessed the impact of these infections in 
different patient groups at risk.   
The specific objectives were: 
1. To evaluate trends in BSIs caused by Candida in Finland during two periods 
1995–1999 and 2004–2007 in a population-based (nation-wide) study, and to 
further analyze the characteristics of candidemia cases according to causative 
species and outcome. (I, II) 
2. To evaluate trends and regional differences in fluconazole consumption and to 
describe prophylaxis policies in tertiary care regions in Finland during 2004–
2007. (II)
3. To evaluate incidence rates, causative species, outcome and different patient 
populations at risk for nosocomial candidemia, as well as fluconazole 
consumption at the Helsinki University Central Hospital during 1987–2004. (I, 
III)
4. To investigate the epidemiological value of REA in C. albicans BSIs at the 
Helsinki University Central Hospital during 1986–1995. (IV)
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4	 Materials	and	methods
A short summary of the study methods, time periods and settings of studies I–IV 
appears in Table 7. 
TABLE 7. Overview of the data sources, time periods and patients of the studies. 
Study Data sources Time 
period
Setting Patients or episodes/
isolates
I NIDR* 1995–1999 Nationwide 479 candidemia 
episodes 
Laboratory-based
identification of 
candidemia
Review of patient charts
1995–1999 HUCH# 86 patients
characteristics and 
outcome
II NIDR* in connection 
with the National 
Population Information 
System
2004–2007 Nationwide 603 candidemia 
episodes 
and outcome
National Agency of 
Medicine 
2000–2007 Nationwide Use of fluconazole
Telephone survey 2004–2007 Five tertiary 
care hospitals
Prophylaxis policies
III Laboratory-based
identification of 
candidemia 
Review of patient charts 
1987–1998 HUCH# 358 patients
characteristics and 
outcome
SIRO** 1999–2004 HUCH# 140 candidemia 
episodes
and outcome
Pharmacy 1991–1999
2003–2004
HUCH# Fluconazole 
consumption in grams
IV Laboratory-based
identification of 
C. albicans bloodstream 
isolates
1986–1995 Helsinki-
Uusimaa 
Health District
142 C. albicans isolates
in 130 patients
*NIDR = National Infectious Diseases Register; **SIRO = Finnish Hospital Infection Program; 
#HUCH = Helsinki University Central Hospital. 
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4.1 Surveillance methodology for bloodstream  
 infections of  the National Infectious   
 Disease Register (NIDR) (I–II) 
In Finland (population 5.3 million), the national health care system is organized into 
five geographically and administratively defined tertiary care districts, each with a 
population ranging from 0.72–1.76 million. Since 1995, all clinical microbiology 
laboratories are required to notify all bacterial and fungal isolates from blood, 
including Candida species, to the National Infectious Diseases Register (NIDR), 
currently mostly electronically. Data collected with each notification include the 
date of specimen, isolated microbe, date of birth, sex, place of treatment, and (since 
2004) each individual’s unique national identity code. A case of candidemia was 
defined as a patient with at least one blood culture that tested positive for Candida 
species. Notifications of the same Candida spp. within three months of the first 
diagnostic sample in the same person were defined as one case. Isolation of the same 
species beyond this time period was defined as separate cases. Through each patient’s 
unique national identity number the data collected during 2004–2007 were linked to 
the National Population Information System to obtain a particular patient’s survival 
at 7 and 28 days from the first positive blood culture (Study II). 
4.2 Description of the hospitals, charts review,  
 and case definitions (I, III, IV)                    
Helsinki University Central Hospital (HUCH) is a tertiary care center with 
~1,700 beds serving a population of 1.66 million in Helsinki and surrounding 
areas in Southern Finland. In some specialties, such as stem cell and solid organ 
transplantations, HUCH provides national services. During the study period 1987–
2004 (III), solid organ and allogeneic stem cell transplantation more than doubled 
in HUCH, from 161 per year in 1987 to 372 per year in 2004. Autologous stem cell 
transplantations increased from 11 per year in 1987 to 95 per year in 1997, and 
thereafter until 2004, varied between 89 and 50 per year (III). 
All patients with at least one blood culture that tested positive for Candida spp. 
during years 1986–1999 (I, III) and with stored blood culture isolates of C. albicans 
between November 1986 and May 1995 (IV) were retrospectively identified from the 
microbiology laboratory logbooks. The following data were retrieved from patient 
charts: date of isolation, place of treatment (HUCH and other acute care hospitals 
in the Helsinki-Uusimaa region), type of medical specialty, underlying conditions, 
central venous catheters (CVCs) and bladder catheters in place, cultures taken 
from these catheters, and the outcome (I, III, IV). Nosocomial versus community 
acquisition of infection (I,III) was individually assessed in each case according 
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to criteria proposed by the CDC [51]. Immunosuppressive status was defined as 
cytotoxic therapy, total body irradiation no more than three months prior the onset 
of candidemia, or systemic cortisone (at least 40mg per day at the onset of the 
cortisone treatment) no more than one month prior the onset of candidemia (I, III). 
The number of blood samples for culture in HUCH between 1989–1992 was 
40,079 (range per year, 9,430–10,918), and between 2000-2004 was 95,341 (range 
per year, 17,745–20,063); data were unavailable between 1993–1999. The mean 
number of blood cultures per 10,000 patient days increased by 70% from 200 during 
1989–1992 (range by year, 200-210) to 340 during 2000-2004 (range by year, 320–
370) (III).
The annual numbers of patient days and discharges were acquired from the 
HUCH administration (I, III). 
4.3 Surveillance methodology for bloodstream  
 infections of the Finnish Hospital Infection  
 Program (III)
The Finnish Hospital Infection Program (SIRO) was established at the end of 1997. 
Two surveillance modules have been executed since 1999, including hospital-wide 
surveillance for nosocomial BSIs. Surveillance is active, prospective, and hospital-
wide, covering all patients admitted to departments offering acute care. Blood 
samples are collected according to clinical decision, and no routine surveillance 
cultures are performed on asymptomatic patients. Candidemia data for the HUCH 
during 1999-2004 were obtained from SIRO. Local infection control nurses 
recorded clinical and microbiological data on a standardized case-record form 
sent monthly to the National Public Institute of Health and Welfare (THL) and 
entered into a common database. An episode of candidemia was defined as a patient 
with at least one blood culture that tested positive for Candida spp., notifications 
of the same species within one week after the first diagnostic sample in the same 
patient were also defined as one episode. The nosocomial acquisition of infection 
was defined according to criteria proposed by the CDC [51]. Data collected with 
each notification included each patient’s unique national identity number, age, sex, 
date of admission, date of specimen, specialty, causative micro-organisms, and their 
sensitivity to antimicrobial agents. Of the underlying conditions and possible risk 
factors, type of delivery, whether the patient was newborn, whether a hematological 
or solid malignancy was present, and whether the patient had undergone organ 
transplantation or hemodialysis were recorded, as was the presence of CVC, prior 
surgery and treatment in an intensive care unit (ICU). The outcome at 7 and 28 days 
from the date of the first positive blood culture for each patient was obtained from 
the National Population Information System by the use of unique person identifiers. 
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4.4 Fluconazole consumption and survey on  
 prophylaxis policy (II–III)
The data on total fluconazole consumption as defined daily doses (DDDs) per 
1,000 inhabitants per year during 2000–2007 in Finland were acquired from the 
National Agency of Medicine (II). Data on fluconazole consumption as grams per 
year (intravenous and per oral) in HUCH, available during the periods 1991–1999 
and 2003–2004, were obtained from the hospital pharmacy (III). 
Infectious diseases specialists in the five tertiary care hospitals were interviewed 
by telephone with a structured questionnaire about written guidelines or routine 
practices for fluconazole prophylaxis in their hospital among the following patient 
groups (adults (≥15 years) and children (<15 years) separately): patients with 
hematological or other malignancy, patients treated in ICU, surgical patients, organ 
transplant patients and premature neonates (III). 
4.5 Description of microbiological methods  
 (I–IV) 
Nationwide studies (I–II)
Detection and species identification of Candida isolates were performed in the 
notifying laboratories according to protocols in use in each laboratory. 
Candidemias in HUCH and the Helsinki-Uusimaa region (I, III–IV) 
The blood specimen collection method included obtaining blood in two pairs of 
aerobic and anaerobic bottles (approximately 10ml and 5ml per bottle for adults and 
children, respectively), from two different sites according to international guidelines. 
Yeasts in circulation were detected with the automated blood culturing system 
(BactecTM; BD, Franklin Lakes, NJ, USA; or Bact/ALERTTM, Marcy l’Étoile, France), 
and the organisms were identified according to standard procedures. Blood culture 
bottles in which yeast cells were observed with gram stain were subcultured on 
Sabouraud agar plates. Primary identification of C. albicans was made with a positive 
germ tube test, and the result was confirmed by the detection of chlamydospores on 
cornmeal-Tween agar plates. If the germ tube tested negative or if no chlamydospores 
could be detected, the yeast strain was identified by fermentation tests (in-house 
prepared tube tests), and from July 1997 on by commercial assimilation tests 
(API20C or ID 32 C; BioMerieux, France). 
C. albicans molecular typing (IV) 
Blood culture isolates were stored at -70°C in skimmed milk glycerol tubes (prepared 
in house) in the microbiology laboratory. In case of multiple sampling from the same 
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patient, as a rule only the first isolate was stored. Re-identification of the revived 
strains was performed according to the standard protocol in use.
Molecular typing by restriction enzyme analysis (REA) was performed in the 
National Public Health Institute (formerly KTL, currently THL). A single colony 
of C. albicans was selected from a Luria agar plate and grown overnight at 37°C 
in 3 ml of YEPD broth (0.3% yeast extract, 1% peptone, 2% glucose) pelleted by 
centrifugation and washed with 1 M sorbitol. The cells were then resuspended in 
100 ml of 1 M sorbitol50 mM KH2PO4 with 3 ml of mercaptoethanol and 20 ml of 
Zymolyase 20T (20 mg/ml in 1 M sorbitol50 mM KH2PO4, ICN Immunochemicals, 
USA). The mixture was incubated at 37°C for 2 h. Spheroplasts thus prepared were 
lysed by the addition of 0.5 ml of GES buffer (30 g guanidium thiocyanate dissolved 
in 10 ml 0.5 M EDTA, pH 8 and 10 ml distilled water followed by the addition of 2.5 
ml of 10% W/vol sarcosyl; the total volume is added to 50 ml with distilled water). 
After 20 min incubation at room temperature, 100 ml of 5 M potassium acetate 
was added, followed by incubation on ice for 20 min and the addition of 0.5 ml of 
chloroform-isoamylalcohol (24:1). The upper phase was separated into a new tube 
after centrifugation. The DNA was then precipitated with 0.5 ml of isopropanol and 
washed with 70% ethanol. The DNA was dissolved and stored in TE (10 mM Tris-
HCl [pH 7.5], 1 mM EDTA) at 4°C until digestion with restriction endonucleases 
EcoRI or MspI for 24 h at 37°C under conditions recommended by the manufacturer 
(Boehringer Mannheim, Mannheim, Germany). Immediately thereafter, the DNA 
fragments were separated electrophoretically on 0.7% agarose gels at 20 V for 20 h. 
The gels were stained with ethidium bromide and photographed. DNA digests of 
12 isolates were run in each gel. For control, a lambda EcoR1/HindIII DNA marker 
(Boehringer Mannheim, Mannheim, Germany) was run in the first and last lane of 
each gel. REA patterns were examined blindly by two of the investigators (JV–V, ES) 
using direct visual comparison of the patterns with the molecular weight standard. 
All samples showing initially similar REA patterns were reanalyzed and confirmed 
through side-by-side comparison. A difference of more than one band in the REA 
pattern was considered as an indication of genetic difference between strains.
4.6 Calculation of incidence and mortality   
 rates and statistical analysis (I–III)
Denominators to calculate age- and sex-specific incidence rates as well as mortality 
rates were acquired from the National Population Information System during the 
periods 1995–1999 (I) and 2004–2007 (II). The average annual incidences were 
calculated by using the total number of cases and population during the study 
periods. To evaluate secular trends, rates of candidemia cases in different age and sex 
groups were calculated for each 6-month period (I) and 12-month period (II). Using 
each patient’s unique national identity number for register linkage, individual death 
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data were acquired for the period 2004–2007 from the same register to determine 
survival at 28 days from the first positive blood culture. The Poisson regression 
model served to assess whether the observed changes in the incidence rates and 
fluconazole consumption were statistically significant. Data were analyzed with Epi-
Info version 6.04 (CDC, Atlanta, Georgia, USA) and SPSS for Windows version 11 
(Chicago, USA) (I-III). Categorical variables were analyzed with the χ2 test using 
Yates`s correction, or Fisher’s exact test as appropriate. Continuous variables were 
analyzed using the Student’s t test or by the Mann-Whitney U test, depending on 
the sample distribution. To compare the case fatality (%) and the proportion of 
Candida spp. in HUCH over time, the 18-year study period was divided into three 
subperiods: 1987–1992, 1993–1998 and 1999–2004 (III). To assess whether there 
was a time trend in the proportion of different Candida species, a generalized linear 
model with log link was fitted to the data (III).
4.7 Ethical aspects 
The Ministry of Social Affairs and Health as well as the Ministry of Education 
and Culture approved the review of the patients’ charts (I, III, IV). The Finnish 
Data protection Authority approved the research use of the SIRO data (III). THL 
authorized the use of NIDR data and the National Agency for Medicines permitted 
the use of the data on fluconazole consumption (I–II).
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5	 Results
5.1 Incidence of candidemia (I–III) 
5.1.1  Incidence in Finland (I–II)
The total number of candidemia cases reported to NIDR was 479 during 1995–1999 
and 603 during 2004–2007. The median age of the patients was 59 and 64 years 
(range 0–94 years), respectively, with male dominance (60–56%). 
The annual incidences according to age- and sex-specific groups appear in 
Table 8. The average annual incidence of candidemia increased between the two 
study periods from 1.9 to 2.9 per 100,000 population (during 1995–1999 and 2004–
2007, respectively). The annual incidence increased from 1.7 per 100,000 population 
in 1995 to 2.2 in 1999, but during 2004–2007 varied from 2.6 to 3.1 with no trend. 
According to the five tertiary care catchment areas, the average incidence varied 
between 1.3–2.2 and 2.4–3.9 during 1995–1999 and 2004–2007, respectively. 
During 1995–1999, the average annual incidence of candidemia was highest at 
9.4 per 100,000 population among infants <1 year of age, although this age group 
constituted only 6% of all candidemia cases. During 2004–2007, however, the 
average annual rate in infants <1 year of age was lower. By age and sex, the incidence 
rates increased most between study periods in patients >65 years of age, from 5.2 
to 8.8 per 100,000 population (during 1995–1999 and 2004–2007, respectively), 
particularly in males. The highest annual incidence, 27.3 per 100,000 population, 
was observed in male infants <1 year of age during 1999, while the incidence was 
lowest in patients 1–15 years of age during both study periods. In males aged 16–65 
years, the incidence rose significantly during 1995-1999, from 1.0 to 2.4 per 100,000 
population (P<0.05 by Poisson regression), but during 2004–2007 the increase was 
non-significant. In all age groups the average annual incidence was higher in males 
than in females during both study periods.   
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TABLE 8. Annual incidences of candidemia by age- and sex-specific groups in Finland, 1995–1999 and 2004–2007. 
Sex
Ratea
Age 
group (y)
1995 1996 1997 1998 1999 1995-1999 2004 2005 2006 2007 2004-2007
Male <1 12.5 10.0 3.3 6.9 27.3 11.9   (18) 6.8 13.6 3.3 13.3 9.2   (11)
1–15 1.2 0.4 0.6 0 0.2 0.5   (12) 0 0 0.2 0 0.1     (1)
16–65 1.0 1.9 1.9 2.1 2.4 1.8 (159) 2.1 2.3 2.5 2.7 2.4 (169)
>65 7.7 6.3 6.1 9.4 7.7 7.4   (97) 13.1 10.2 12.5 13.2 12.2 (156)
All 1.9 2.1 2.1 2.5 2.8 2.3 (286) 3.1 3.0 3.4 3.7 3.3 (337)
Female <1 6.5 3.4 0 3.6 21.3 6.9   (10) 3.6 3.5 10.4 0 4.4     (5)
1–15 0.6 0.4 0.6 0.2 0.6 0.5   (12) 0.2 0.2 0.7 0.7 0.5     (8)
16–65 1.0 0.8 1.1 1.2 0.8 1.0   (84) 1.8 1.7 1.8 2.0 1.8 (126)
>65 4.2 4.3 3.4 3.6 4.2 3.9   (87) 7.4 6.0 6.4 6.4 6.6 (127)
All 1.5 1.4 1.4 1.5 1.6 1.5 (193) 2.5 2.2 2.6 2.6 2.5 (266)
All <1 9.6 6.6 1.7 5.3 24.4 9.4   (28) 5.2 8.7 6.8 6.8 6.9   (16)
1–15 1.0 0.5 0.6 0.1 0.4 0.5   (24) 0.1 0.1 0.4 0.3 0.3     (9)
16–65 1.0 1.4 1.5 1.7 1.6 1.4 (243) 2.0 2.0 2.2 2.3 2.1 (295)
>65 5.4 5.0 4.4 5.7 5.6 5.2 (184) 9.7 7.7 8.8 9.1 8.8 (283)
All 1.7 1.7 1.8 2.0 2.2 1.9 (479) 2.8 2.6 3.0 3.1 2.9 (603)
aRate per 100,000 population (number of cases). 
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5.1.2  Incidence in HUCH (I, III)
A total of 364 episodes of candidemia were observed during 1987–2004 (range by 
year, 12–32) in 358 patients. Most (96%) of the infections became evident >2 days 
after hospital admission; 4% were related to a preceding hospital stay. 
Incidences of candidemia by species appear in Figure 1. The average annual 
incidence varied from 0.41 per 10,000 patient-days during 1987–1992 to 0.37 during 
1993–1998 and to 0.44 during 1999-2004 (range by year, 0.26–0.59); no increasing 
trend was detected in annual incidence. The annual incidence of C. glabrata for the 
entire study period increased (P<0.01), while the incidences of C. albicans or non-C. 
albicans spp. as a whole showed no statistically significant trend. 
FIGURE 1. Candidemia incidence per 10,000 patient days at the Helsinki University Central 
Hospital, 1987–2004.
5.2 Patient characteristics and underlying   
 conditions in HUCH (I, III) 
The median age of the patients with candidemia was 50 years (range, <1–89 years) 
and 59% were male; no changes were detected in age and gender distribution during 
1987–2004. The proportion of patients treated in the ICU increased from 24–27% 
during 1987–1998 to 44% in 1999–2004 (P<0.05). This increase was related to both 
surgical patients and newborns representing half of ICU patients. Overall, the 
proportion of surgical patients increased from 43–46% during 1987–1998 to 55% 
during 1999–2004, but this increase did not reach statistical significance (P=0.05). 
The proportion of hematological patients decreased significantly from 21–27% 
to 11%, and patients with solid malignancies from 24–25% to 9% by 1999–2004 
(P<0.05). Organ transplantation (solid organ or bone marrow transplant) preceded 
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candidemia in only 2–5% of the patients. Information on a CVC in place was 
available for 347 episodes (95%): a catheter was present in 77–78% of those episodes 
during 1987–1998 and in 72% during 1999–2004. None of the cases had human 
immunodeficiency virus (HIV) infection.
 A summary of patient characteristics and predisposing factors available only 
from chart review in HUCH during 1987–1998 appears in Table 9. At the onset of 
candidemia, all cases had at least one predisposing factor. The main predisposing 
factors were immunosuppressive state or leucopenia and gastrointestinal surgery. 
Biopsy-proven deep Candida infection was rare. 
TABLE 9. Patient characteristics and predisposing factors in patients with nosocomial 
candidemia in HUCH, 1987–1998.
Characteristic or predisposing factor*
Number of patients, (%)
1987–1992 
N = 128
1993–1998
N = 96
Duration of hospital stay prior onset of 
candidemia 
21 days (range 0–165) 17 days (range 0–435)
Bladder catheter 44 (34) 37 (38)
Immunosuppressive state** 58 (45) 44 (46)
Leucopenia*** 26 (20) 23 (24)
Preceding gastrointestinal surgery 50 (39) 28 (29)
Severe trauma 6   (5) 6   (6)
Biopsy-proven deep Candida infection 6   (5) 12   (9)
* one patient can have several predisposing factors; ** defined as cytotoxic therapy or total 
body irradiation ≤3 months before onset of candidemia or systemic cortisone (dose ≥40 mg 
daily at onset of cortisone treatment) ≤1 month before onset of candidemia; *** leucocytes ≤1 
x 10E9/l and/or neutrophils ≤0.5 x 10E9/l.
5.3 Causative Candida species (I–III)  
Distribution of Candida species in Finland (I–II)
The most frequent Candida spp. encountered was C. albicans contributing to 335 
(70%) cases during 1995–1999 and 406 (67%) cases during 2004–2007 (Figures 2 
and 3). The proportion of non-C. albicans spp. as a whole remained constant in 
Finland. The most common of these, C. glabrata, increased in proportion from 
9% in 1995–1999 to 19% in 2004–2007, but its proportion did not change during 
either of the study periods. C. krusei decreased in proportion from 8% to 3%, while 
C. parapsilosis remained stable at 5% between both periods of observation. The 
other species identified were C. pelliculosa (5 cases), C. guilliermondii (5 cases), C. 
lusitaniae (4 cases), C. dubliniensis (3 cases), and C. rugosa (1 case). The causative 
Candida spp. was unknown in 14 cases (3%) during 1995–1999 and in 4 cases (1%) 
during 2004–2007, respectively. Two Candida species were reported in 7 (1%) cases 
during 2004–2007. 
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According to the five tertiary care districts in Finland, the proportion of species 
other than C. albicans peaked during 2004–2005 in Turku at 44–42% and in 2004 in 
Tampere at 42%, consisting mainly of both C. glabrata and C. parapsilosis. 
FIGURE 2. Distribution of Candida species in Finland, 1995–1999.
FIGURE 3. Distribution of Candida species in Finland, 2004–2005.
Distribution of Candida species in HUCH (I, III)
A total of 408 isolates were recovered from samples obtained during 364 candidemia 
episodes in HUCH during 1987–2004. Polymicrobial infections accounted for 11% 
(41) of the episodes; two Candida spp. were recovered from three episodes. The 
species of Candida was unknown in 1% of the episodes during 1987–1998 and in 5% 
during 1999–2004. C. albicans (65%) ranked the most common causative species for 
the entire study period, followed by C. parapsilosis (13%), C. glabrata (9%), C. krusei 
(5%), and C. tropicalis (2%). The proportion of C. albicans decreased from 71% (range 
by year, 65–82%) to 67% (range by year, 50–83%) between the subperiods 1987–
1992 and 1993–1998, and was 58% (range by year, 36–78%) during 1999–2004. The 
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proportion of C. albicans decreased significantly from 69% to 58% between 1987–
1998 and 1999-2004, respectively (P<0.05), while no statistically significant trend 
was detected between the subperiods for non-C. albicans species as a whole. The 
total number of episodes caused by C. glabrata was 31, 19 of which occurred during 
1999–2004; the proportion of C. glabrata increased from 3% during 1987–1992 to 
14% by 1999–2004 (P<0.01), but no other significant trend in species distribution 
was detected. 
5.4 Fluconazole consumption and prophylaxis  
 policies (II–III) 
Total fluconazole consumption in Finland and in the five tertary care districts 
appears in Figure 4. Total consumption increased significantly (P<0.01) from 19.57 
DDDs per 100,000 population in 2000 to 25.09 in 2007 in all five regions. Per oral 
consumption comprised 89% (range by year, 88-90%) of total fluconazole use; the 
rest was parenteral use (II). 
In HUCH, the data on fluconazole use were available for periods 1991–1999 
and 2003–2004. Fluconazole use increased more than six-fold from 22 grams per 
10,000 patient days in 1991 to 145 grams in 2004. Per oral use increased from 6 to 
79 grams per 10,000, and intra venous use from 15.5 to 66 grams per 10,000 patient 
days by 2004 (III). 
FIGURE 4. Use of fluconazole in daily defined doses (DDD) by tertiary care center districts in 
Finland, 2000–2007.
Prophylactic policies in Finnish tertiary care centers (II)
Fluconazole prophylaxis was used in all five tertiary care centers for adult acute 
leukemia patients treated with intensive chemotherapy over each period of 
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neutropenia, mostly since 2000, and in one center since 2007 (Table 10). In addition, 
in most centers, pediatric patients with acute leukemia received fluconazole 
prophylaxis during neutropenia. Fluconazole prophylaxis was administered to adult 
stem cell recipients in only one center, unlike pediatric stem cell recipients, who 
received fluconazole prophylaxis in most centers. Solid organ transplantations were 
performed in only one tertiary care center, and since 1998, only liver transplant 
recipients (adults and children) received fluconazole prophylaxis beginning 
immediately prior to or during surgery until at least 5 days postoperatively. In four 
of the five tertiary care centers, premature infants received fluconazole prophylaxis 
for two to six weeks or during invasive monitoring. All four centers have used 
prophylaxis since at least 2002–2004. 
No tertiary care center used fluconazole prophylaxis in adult or pediatric 
patients with solid malignancies, intensive care patients or surgical patients.  
TABLE 10. Fluconazole prophylaxis policies in the five tertiary care centers according to 
patient populations at risk. 
Patient group Prophylaxis policy
Adult patients
Hematological patients 
   Acute leukemia during neutropenic phase
   Stem cell recipients during neutropenic 
   phase
Patients with malignancies, ICU* patients 
and surgical patients
Liver transplant recipients ≥5 days 
postoperatively**
Other solid organ transplant recipients**
Routinely in four centers since 2000, in one 
center since 2007. Written guidelines in 
three centers.
Routinely in one center, written guidelines 
since 2007.
No routine prophylaxis.
Routinely since 1998, no written guidelines.
No routine prophylaxis.
Pediatric patients
Hematological patients
   Acute myeloid leukemia during 
   neutropenic phase
   Acute lymphoid leukemia during 
   neutropenic phase
   Allogeneic transplant recipients during 
   hospital stay***
   Autologous transplant recipients during 
   hospital stay or neutropenic phase
Routinely in four centers since 1998-2000. 
Written guidelines in three centers.
Routinely in two centers. Written guidelines 
in one center.
Routinely in three centers since 2000. 
Written guidelines in three centers.
Routinely in four centers since 2000.
Written guidelines in two centers.
Premature neonates 2–6 weeks or during 
invasive monitoring
Routinely in four centers since 2002-2004. 
Written guidelines in two centers.
Patients with malignancies, ICU patients, 
and surgical patients
No routine prophylaxis.
Liver transplant recipients ≥5 days 
postoperatively**
Routinely since 1998, no written guidelines.
Other solid organ transplant recipients** No routine prophylaxis. 
* ICU = Intensive care unit.
** Solid organ transplantations are performed in only one center.
*** Allogeneic stem cell stransplantations are performed in only three centers.
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5.5 Patient outcome (I–III) 
Outcome in population-based study in Finland during 2004–2007 (II)
Data on outcome were available for 598 (99%) case-patients during 2004–2007, 208 
(35%) of whom died within one month of the first blood culture that tested positive 
for Candida. The case-patients who died were significantly older than those who 
survived (median age, 70 vs. 62 years; P<0.01). The one-month case fatality varied 
by year between 32–38% and by tertiary care region between 31–37%. The average 
annual mortality rate was 0.99 deaths per 100,000 population (range by year, 0.89–
1.08; range by district, 0.91–1.27). 
Oucome in HUCH (I, III)
During 1987–2004, 113 (31%) candidemia patients died within one month of the 
onset of candidemia. Patients who died were significantly older than those who 
survived (median age, 58 vs.45 years; P<0.01), more likely to have had candidemia 
caused by C. albicans than other species (77% vs. 60%; P<0.01), or to have had 
hematological malignancy (27% vs. 15%; P<0.05), and less likely to have stayed in 
an ICU (25% vs. 36%; P<0.05). The overall proportion of one-month case fatality 
remained stable over the three study periods (range per period, 30–33%). Among 
the different patient groups, case fatality increased in patients with hematological or 
solid malignancies, but not in newborns, patients with previous surgery or intensive 
care patients (Table 11). Of the 14 patients with organ transplants, 7 (50%) died 
within one month.
TABLE 11. Case fatality within one month of the onset of candidemia according to underlying 
conditions and risk factors in Helsinki University Central Hospital during 1987-2004
Underlying condition or 
risk factor*
Number of deaths, %
1987–1992 1993–1998 1999–2004 Overall
Preceding surgery
N = 177
20 34% 13 32% 18 23% 51 29%
Stay in the ICU**
N = 120
13 37% 3 13% 12 19% 28 23%
Hematological malignancy 
N =  69
10 37% 12 46% 8 50% 30 43%
Solid malignancy
N = 68
 8 26% 8 33% 5 38% 21 31%
Newborn status
N = 62
 5 26% 0 3 9% 8 13%
Organ transplantation
N = 14
 3 100% 0 4 67% 7 50%
* one patient may have several underlying conditions or risk factors; ** ICU=Intensive care 
unit.
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5.6 Epidemiological typing of C. albicans (IV) 
DNA types were highly dispersed among the study population as 118 distinct DNA 
types were identified among 142 C. albicans strains from 130 patients. As many as 13 
DNA types (codes CA1–CA13) were observed more than once, and 105 DNA types 
(code CAx) were unique. Both restriction enzymes yielded similar results; neither 
was superior in discriminating between DNA types.
One patient yielded a DNA type CA3 and a subtype CA3.1 on consecutive 
blood cultures, and only one patient yielded two DNA types (CAx and CAx) from 
subsequent blood cultures taken four days apart. One patient had two separate 
episodes of candidemia with a time interval of 279 days, and the same DNA type 
CA6 was isolated once during the first episode and twice with a time interval of 33 
days during the second episode of fungemia.
There was no evidence in the typing results, which suggests epidemic clustering 
of the patients. Because of hospital transfers, the data were also analyzed according 
to the unit in which the patient was hospitalized three days prior to the first positive 
blood culture for yeast, but no clusters were detected. The greatest number of 
C. albicans blood culture strains was from the unit for gastroenterologic surgery 
(n = 27) and from the Surgical Hospital (n = 28), which perform most of the solid 
organ transplantations in HUCH. In 3 patients of almost 30 in these units, the same 
subtype was observed, but these candidemia cases were distributed across several 
months and in different bed wards. Despite the abundant patient transfers between 
bed wards and units performing invasive and non-invasive diagnostic procedures 
in HUCH, only one subtype found in 2 of a total of 63 patients was shared between 
different services.
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6	 Discussion
This study characterizes the epidemiology of candidemia in Finland during two 
separate five-year periods of nationwide population-based surveillance. Overall, 
annual as well as age- and sex-specific incidence rates were calculated, along with the 
outcome of illness during the latter study period. In addition, fluconazole prophylaxis 
policies in all five tertiary care centers as well as fluconazole consumption in Finland 
were analyzed during 2004–2007. Over 18 years of observation, the incidence, 
predisposing factors, patient characteristics, and outcome of candidemia, as well as 
fluconazole consumption, were studied in the largest tertiary care center (TCC) in 
Finland. The C. albicans blood culture isolates from patients within a defined region 
in Finland were characterized with the molecular typing method. The main findings 
and limitations of this study are dicussed below. 
6.1 Candidemia incidence rates 
6.1.1  Candidemia incidence in Finland 
Our nationwide population-based studies show that the incidence of candidemia 
in Finland is relatively low. During the period 1995–1999, however, we observed a 
consistent year-to-year increase, and the average annual incidence of candidemia 
increased between the periods 1995–1999 and 2004–2007 from 1.9 to 2.9 per 100,000 
population, respectively. Instead, candidemia incidence in Finland remained stable 
during the years 2004–2007. 
The rates we observed are only one third to one fourth of those reported from 
the USA, with most reports ranging from 6.0 to 10.0 per 100,000 population [23, 82–
84] Two of these studies were based on sentinel surveillance implemented in selected 
urban areas, and thus they may not be representative of the general US population. 
Low incidence rates comparable to ours have been reported from Norway and 
Canada [11, 17], with somewhat higher reported from elsewhere in Europe [87, 
89], and considerably higher rates (10.4 per 100,000 population) from Denmark 
[85, 162]. Extended surveillance periods have been reported from Iceland (1980–
2006) and Norway (1991-2003), both with an increasing incidence over time [17, 
86]. The increasing rate of candidemia we observed between periods in the 1990s 
and 2000s is in line with those of other population-based studies, thus highlighting 
the growing importance of bloodstream infections (BSIs) caused by Candida spp. 
among vulnerable hospitalized patients. 
The constant male dominance we observed is consistent with most reports from 
the USA and Europe [17, 82, 83, 85], although not unequivocally [11, 23]. By age 
and sex, incidence rates increased in patients >65 years of age, particularly in males 
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(Table 8). Incidences comparable to ours in this age group have been observed in 
Norway and Spain [17, 89], while rates have been considerably higher in Denmark, 
Iceland, and the USA [83, 85, 86]. During the 1990s in Finland, the highest age-
specific incidence rate was in infants <1year of age. Interestingly, in the two youngest 
age groups (<1 year-15 years of age), the incidence in Finland was lower during the 
2000s than in the 1990s, partly due to the fading of an outbreak of C. parapsilosis in 
the neonatal intensive care unit (NICU) of the HUCH since 2002. Clearly higher 
incidence rates (20–75 per 100,000 population) in infants <1 year of age have been 
reported from North America and Spain [11, 83, 89], while incidences in other 
Nordic countries have been only somewhat higher than in Finland [11, 17, 83, 85, 
86, 89]. 
The conspicuous differences in candidemia rates between countries may be real, 
but may also be due to differences in the representativeness and age distributions of 
the study populations as well as variations in patterns of health care delivery and 
clinical practices, including the frequency of using blood cultures in diagnostics, 
differences in antibiotic use patterns, and the resistance situation. In a previous 
study, Candida spp. represented only 4% of all pathogens in nosocomial BSIs in 
Finland, and the prevalence of antibiotic resistance among bacterial findings was 
lower than in the USA [64].
While our laboratory-based surveillance data of candidemia are representative 
of the entire population, the data on patient characteristics collected with each 
notification are limited, and the proportion of nosocomial vs. community-onset 
candidemias is unknown. 
6.1.2  Candidemia incidence in HUCH 
Our 18-year study in the largest tertiary care hospital in Finland showed a constant 
low incidence of candidemia between 0.26 and 0.59 per 10,000 patient days. This is 
surprising given the increase in high-risk activities for invasive fungal infections, 
such as solid organ and stem cell transplantations, which more than doubled during 
our study. Non-nosocomial candidemia was very rare in HUCH, as only 4% of 
candidemia cases were detected within two days of hospitalization, which contrasts 
sharply with reports from the USA, where one fifth of candidemias develop in 
patients before or on admission to the hospital [83, 258].
While several centers in Europe have reported incidence rates comparable to 
ours [5, 10], higher rates have been observed in Belgium, France, and Italy [16, 168, 
172]. In addition, the rate we observed in HUCH is one fourth to one sixth of the 
rates reported from the USA [23, 127]. In-hospital incidence rates in the USA and 
Europe have been largely stable or increasing during 1990-2000s, but decreasing 
incidence has been reported from Belgium [172] and also from intensive care units 
(ICUs) in the USA during the 2000s [15]. However, a 3.5-fold increase was observed 
during 1998–2008 in Australia, particularly in adult TCCs [173]. The current overall 
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trends of candidemia incidence are not clear. The reported rates in Europe have 
been lower than in the USA, and while many centers have observed stable or even 
decreasing incidences, also considerable increases have been reported.  
This considerable variation in rates in different centers highlights major 
differences in treatment practices, in vulnerable patient populations, and in 
diagnostic activity (e.g., the frequency with which blood cultures are used in 
diagnostics). Also, the manner in which the surveys are conducted (i.e., single-
center vs. multicenter studies) may affect the results. While the number of patients at 
risk for Candida BSIs appears to be increasing, more of the care of these patients has 
shifted to non-ICU settings, and patients with indwelling central catheters are cared 
for at home. This change of practice may in part increase the rates of candidemia 
outside traditional high-risk areas [173]. Definitions of nosocomial infection may 
vary, as can determining whether an infection is related to previous hospitalizations 
[258]. During our study, the number of blood cultures per patient day increased 
markedly; thus, the stable incidence we observed is not explained by low diagnostic 
activity. 
Our study has several limitations. The number of candidemias during 1987–
1998 was acquired from microbiology laboratory logbooks, and during 1999–2004, 
from the Finnish Hospital Infection Program (SIRO) (this different data source may 
affect our observed rates). The data on blood samples taken for culture covers only 
part of our study period, although with a consistently rising trend. 
6.2 Patient characteristics in HUCH
The proportion of ICU patients increased significantly during the study period and 
became one of the major patient groups at risk. The proportion of surgical patients 
increased, while those of traditional risk groups (i.e., patients with hematological or 
solid malignancy) declined. 
Our study confirms the importance of surgery (particularly gastroenterology 
surgery), treatment in the ICU, and hematological and solid malignancies as factors 
contributing to nosocomial candidemia. Several centers around the world have 
reported rising rates of candidemia among intensive care patients [5, 10, 92, 165, 
172, 174, 183]. The high proportion of surgical patients we observed is in accordance 
with previous observations from Europe and Australia [10, 12, 173], but contrasts 
with a study from the USA in which surgical patients comprised 18% of candidemias 
[83]. The decline in the proportion of hematological patients in HUCH also parallels 
the implementation of fluconazole prophylaxis in this patient group. 
None of the patients with candidemia had HIV infection, which reflects the low 
prevalence of HIV infection in Finland [259]. The proportion of patients with HIV-
infection among candidemia patients has been high ranging from 10% to 15% in the 
USA [83, 84], while in Europe, these patients comprise 0.6–3% of candidemia cases 
[10, 12, 92]. 
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 The proportion of newborns among candidemia patients increased during 
1999–2004 and has been associated with a prolonged outbreak in premature neonates 
that has subsided since 2002 [194]. Newborns (patients <1 year) have accounted for 
~8% of candidemia patients in several centers in Europe [12, 92]. 
The patient data recorded in the SIRO are limited, and we did not review patient 
charts during the years 1999–2004. In addition, the data abstracted from patient 
charts have limitations: the information is not uniform, is sometimes hand-written, 
or is missing altogether. Due to our long observation period, and thus multiple 
changes in hospital departments, we could not analyze patient days according to 
specialty. 
6.3 Causative Candida species 
Our nationwide population-based study observed no changes in the proportion of 
C. albicans between the 1990s and 2000s in Finland, but the proportion of C. glabrata 
increased considerably from 9% to 19%, ranking second after C. albicans during 
the 2000s. Other Candida species were isolated only rarely, while the proportion 
of C. krusei decreased from 8% to 3% between our study periods. Accordingly, the 
predominating causative organism in HUCH during our 18 years of observation was 
consistently C. albicans; its proportion decreased significantly, however, while that 
of C. glabrata increased.
The stable predominance of C. albicans in Finland contrasts with several reports 
from the USA, Australia, and Europe, in which the proportion of non-C. albicans 
species has increased to 40-56% [14, 15, 22, 23, 65, 83, 85, 171, 173, 183], but is 
in line with nationwide studies from Iceland and Norway as well as with several 
reports from centers in Europe [5, 17, 86, 172, 182]. The precise pattern of causative 
species varies across countries and centers [22, 89, 173, 175], but some centers in 
the USA and Europe report that the incidence of C. glabrata has risen to second or 
third in rank [13, 15, 82, 260, 261]. The shift in causative Candida spp. remains still 
to be clarified, while the increasing proportion of C. glabrata has been associated 
with many factors including geographical variation, exposure to azoles or antifungal 
agents, differences in demographics and in patient comorbidites, and the ability of 
blood culture systems to isolate different Candida species [15, 22, 262]. Interestingly, 
in HUCH the proportion of C. glabrata as a causative species rose only after 2001, 
while the consumption of fluconazole already began increasing through the 1990s. 
The cause of the decrease we observed in the proportion of C. krusei is unknown, but 
may be associated with patient demographics and underlying conditions.  
Limitations to our study include a growing number of unknown Candida spp. 
(1% vs. 5 %, respectively) reported concomitantly with the shift in the use of data 
from SIRO. Changes in blood culture systems in HUCH over the years may also 
have contributed to changes in causative species. 
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6.4 Fluconazole consumption and prophylaxis  
 policies in Finland 
The consumption of fluconazole in HUCH increased six-fold during 1987–2004. 
The total consumption of fluconazole increased in all five regions in Finland during 
2000–2007, which also suggests increased usage of fluconazole in tertiary care 
hospitals. 
The consumption of fluconazole in HUCH is in the same range as that of a report 
from one TCC in Belgium during 1994–2004, but a multicenter study in Switzerland 
in 2000, and another in the USA in 1993, reported clearly lower consumption [5, 165, 
182]. No association was observed between the use of fluconazole and distribution 
of Candida species causing BSIs in Switzerland or in Belgium [5, 182]. The role 
of fluconazole consumption in the shift of causative Candida species remains 
inconclusive, as several reports have observed the effect [13, 15, 165, 261], while 
others have not [5, 17, 22, 182]. 
Prophylaxis with fluconazole was used systematically during 2000s in patients 
with acute leukemias, liver transplant patients, and in premature infants in Finland. 
The prophylactic use of fluconazole in neonates and pediatric leukemia patients 
along with improved infection control practices may have contributed to the 
observed reduction in candidemia rates in patients <16 years of age. Despite the 
increase in fluconazole consumption in HUCH as well as in tertiary care center 
catchment regions in Finland, we observed no shift towards non-C. albicans species 
as a whole, but among them the proportion of C. glabrata increased. 
Data on fluconazole usage in HUCH were available only for the years 1991–
1999 and 2003–2004. Data on fluconazole consumption in HUCH, however, is 
general year-to-year use of fluconazole obtained from the hospital pharmacy with 
trends in the distribution of causative species, which is not generalisable to the 
individual patient level. Moreover, our nationwide survey is an ecological study in 
which we used data on the total consumption of fluconazole in different tertiary care 
catchment regions, in connection with our population-based data on incidence rates, 
to make inferences about individual patients based on average population statistics. 
In addition, with only laboratory-based reporting (NIDR), differentiating between 
nosocomial and community-onset infection is impossible. Consequently, we could 
not calculate fluconazole consumption as DDDs per patient-day and have no data 
on sensitivity to fluconazole. A further limitation of our study is that the guidelines 
and routine prophylaxis policies presented here are limited to patients in tertiary 
care centers, and thus affect candidemia rates in these hospitals and not in health-
care institutions as a whole. Regarding infectious diseases, however, physicians of 
the centers play a key consulting role in their districts on policies affecting groups at 
high risk for candidemia. Furthermore, we did not inquire about the dosing of the 
prophylaxis, so the adequacy of the prophylaxis remains unknown. 
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6.5 Patient outcomes 
The proportion of crude case fatality by one month remained stable at 30–33% in 
HUCH, and at 35%, remained stable in our nationwide study during 2004–2007 as 
well. 
The case fatality rates we observed are in line with those of reports from the USA 
and most European countries [12, 23, 91, 92, 185], despite reports of clearly higher 
rates of 44–61% [9, 16, 89, 171, 174, 175, 183]. Patients who died were more likely to 
be old and to have hematological malignancy or candidemia caused by C. albicans, 
thus confirming the contribution of serious underlying diseases, treatments causing 
immunosuppression, and older age to the high case fatality rate. In HUCH, the low 
case fatality rate in patients treated in ICU reflects the fact that the majority of them 
were premature newborns with candidemia caused by C. parapsilosis. Patients with 
a previous organ transplant had the highest case fatality at 50%, but they were few 
(14). 
A limitation of our study is that we had no data on deaths related directly to 
candidemia, and thus could not calculate attributable mortality, but only all-cause 
mortality. 
6.6 Epidemiological survey of C. albicans 
The 142 blood culture isolates of C. albicans from 130 patients were highly dispersed 
when analyzed using restriction-enzyme analysis (REA). 
Our study covered a period of more than eight years and seven separate acute 
care hospitals, one of which was located at six different sites. This set-up should 
reduce the bias potentially associated with small patient materials from a single center 
where endemic subtypes could be prevalent. REA differentiated efficiently between 
C. albicans strains, and both restriction enzymes showed similar discriminatory 
power. Although a minority, among consecutive isolates from the same patient 
(11), REA demonstrated highly reproducible DNA patterns. No clusters or endemic 
subtypes were observed in the hospitals involved despite the abundant transfer of 
patients between them.  
REA has been used to distinguish strains of C. albicans, although when compared 
with pulsed-field gel electrophoresis (PFGE) karyotyping, the results have been 
conflifting [45, 207, 263–266]. The application of these two methods in succession 
enhances differentiation between strains [263, 265, 267]. Using computer programs 
to analyze digitized REA patterns improves the accuracy of strain discrimination 
and the speed of analysis, while modern methods that use DNA amplification by 
PCR could offer accurate strain discrimination of both C. albicans and non-C. 
albicans spp. [102, 142, 264].
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7	 Conclusions	and	future		 	 	
	 considerations
The incidence of candidemia in Finland is globally relatively low, but did increase 
during the period 1995-1999, and between the two study periods in the 1990s and 
2000s. In HUCH, the incidence of candidemia remained low and constant during 
1987–2004, and consisted almost exclusively of nosocomial infections. Candida 
spp. are an important cause of nosocomial bloodsream infections in Finland, and 
continued surveillance is necessary to determine the overall trends and to reduce 
the impact of these infections in the future. Multicenter and nationwide studies 
contribute to a comprehensive data set across all susceptible patients groups and to 
the true influence of healthcare delivery on candidemias, while surveys performed 
in a hospital have tremendous value for therapeutic decision making and preventive 
measures at the local level. Surveillance to monitor the burden of disease and the 
emergence of resistance among the general patient population and among high risk 
patient populations should continue.
In nationwide studies, incidence rates increased in older age groups, particularly 
in males, while in patients in the younger age groups (<1 year-15 years of age), had 
lower incidence during the 2000s than in the 1990s in Finland. In HUCH, the study 
implied a significant shift in patient populations at risk, with surgical and intensive 
care patients gaining predominance. A future challenge is to uniformly recognize 
the adult high-risk patients treated in surgical wards and intensive care units as 
such and to apply them measures to prevent nosocomial infections and adequate 
antifungal prophylaxis. 
The predominant causative species in Finland and in HUCH is C. albicans, 
but the proportion of C. glabrata increased considerably. While this increase stems 
partly from a change in blood culture systems and an older patient population 
(C. glabrata is rare in neonates), it may reflect a true shift in species causing 
candidemias. The increase in the proportion of C. glabarata has several implications 
both for microbiology laboratory (in identifying the clinical isolates in species-level 
and in antifungal susceptibility testing) and for clinical decicion making in choosing 
prophylactic, pre-emptive, and empirical treatments. 
Fluconazole consumption increased not only in HUCH, but in all five tertiary 
care center regions in Finland as well. Fluconazole prophylaxis was systematically 
implemented in traditional high-risk patient groups (i.e., patients with acute 
leukemias, liver transplant patients, and in premature infants) and most probably 
contributed to the observed decrease of candidemia rates in these subpopulations. 
The role of antifungal prophylaxis with fluconazole in amplifying the shift in causative 
Candida species is inconclusive, but requires continued vigilance in the future.  
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The proportion of crude case fatality per one month was high, at 30–35%, and 
remained stable. This high case fatality ratio emphasizes the need for continuous 
surveillance to identify changes in predisposing factors to optimize preventive 
policies, including the use of antifungal prophylaxis, particularly in new risk 
groups. Given the substantial excess mortality due to candidemia and the difficulties 
encountered in administering early and effective antifungal therapy, better methods 
of prevention will decrease candidemia-associated mortality more than will advances 
in therapy. 
Epidemiological typing with REA showed no clusters or endemic subtypes 
in the hospitals involved. Rather, as a rule, each patient was infected by a unique 
C. albicans strain, implying an endogenous source of candidemia. In the future, 
molecular methods for investigating suspected outbreaks caused by Candida spp. 
should be available in Finland, also.
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